UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the fiscal year ended December 31, 1997
or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ______ to _______
Commission File No. 1-13392
US DIAGNOSTIC INC.
-----------------------------------
(Name of Registrant in its charter)
DELAWARE 11-3146389
- ------------------------------- ---------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)
777 SOUTH FLAGLER DRIVE, SUITE 1201 EAST, WEST PALM BEACH, FLORIDA 33401
- ------------------------------------------------------------------ ---------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (561) 832-0006
SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT: None
SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT:
Common Stock, $.01 par value
Indicate by check mark whether the registrant: (1) filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the 12 months (or for such shorter period that the registrant was required to
file such report(s), and (2) has been subject to the filing requirements for the
past ninety (90) days. YES [X] NO [ ]
Indicate by check mark here if there is no disclosure of delinquent filers in
response to Item 405 of Regulation S-K contained in this form, and no disclosure
will be contained, to the best of registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-K
or any amendment to this Form 10-K. [ ]
The aggregate market value of voting and non-voting common equity held by
non-affiliates of the registrant as of April 14, 1998 was approximately
$89,954,096 based on the average bid and asked prices of the Common Stock on
April 14, 1998.
As of April 10, 1998, 22,936,433 shares of Common Stock of the registrant were
issued and outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Part III information will be filed with the Securities and Exchange Commission
pursuant to General Instruction G(3) to Form 10-K in an amendment to this Form
10-K.
<PAGE>
PART I
Except for historical information contained herein, certain matters
discussed herein are forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Any
statements that express, or involve discussions as to, expectations, beliefs,
plans, objectives, assumptions or future events or performance (often, but not
always, through the use of words or phrases such as will likely result, are
expected to, will continue, is anticipated, estimated, projection, outlook) are
not statements of historical facts and may be forward-looking. Forward-looking
statements involve estimates, assumptions and uncertainties that could cause
actual results to differ materially from those expressed in the forward-looking
statements. These forward-looking statements are based largely on the Company's
expectations and are subject to a number of risks and uncertainties, including
but not limited to, economic, competitive, regulatory, growth strategies,
available financing and other factors discussed elsewhere in this report and in
the documents filed by the Company with the SEC. Many of these factors are
beyond the Company's control. Actual results could differ materially from the
forward-looking statements made. In light of these risks and uncertainties,
there can be no assurance that the results anticipated in the forward-looking
information contained in this report will, in fact, occur.
Any forward-looking statement speaks only as of the date on which such
statement is made, and the Company undertakes no obligation to update any
forward-looking statement or statements to reflect events or circumstances after
the date on which such statement is made or to reflect the occurrence of
unanticipated events. New factors emerge from time to time and it is not
possible for management to predict all of such factors, nor can it assess the
impact of each such factor on the business or the extent to which any factor, or
combination of factors, may cause actual results to differ materially from those
contained in any forward-looking statements.
ITEM 1. BUSINESS.
GENERAL
US DIAGNOSTIC INC. (the "Company") is the nation's largest operator of
outpatient diagnostic imaging and related facilities ("Facilities") with 126
locations owned and operated nationwide. The majority of services provided by
the Company involve the use of Magnetic Resonance Imaging ("MRI"), Computed
Axial Tomography ("CT"), mammography, x-ray and ultrasound equipment. The
Company also offers nuclear medicine services utilizing Single Photon Emission
Tomography ("SPECT") equipment, as well as radiation oncology and therapy
services utilizing linear accelerators and related equipment. The use of the
type of imaging and treatment equipment employed by the Company has grown
rapidly in recent years because it allows physicians to quickly and accurately
diagnose and treat a wide variety of diseases and injuries without exploratory
surgery or other invasive procedures, which are usually more expensive, riskier
and more debilitating for patients.
Of the locations where patients are seen, 110 are fixed sites and 16 are
mobile sites. See "Recent Developments". The Company believes that the mix of
services provided at its Facilities, which include anatomical and functional
imaging, (i) provides cross referral opportunities, and (ii) increases the
Company's ability to serve as a one-stop provider of such services to
increasingly important managed care organizations.
The Company is in the process of implementing a four part strategy as
follows: (i) continue the cost reduction plan implemented in the first quarter
of 1998. The cost reduction plan, now underway, includes a significant reduction
in nonessential staff and other consolidation synergy, heretofore not applied.
The aggregate reduction of employee-related expenses is expected to save
approximately $5
2
<PAGE>
million annually. The Company continues to focus upon other efficiencies in its
operations; (ii) divest non-core assets and focus upon the Company's core
business. In addition to the sale of MDI described in "Recent Developments"
below, the Company is currently reviewing other non-core assets and will pursue
other such sales as warranted; (iii) refinance the Company's long term debt, and
(iv) once the first three steps have been accomplished, institute a sustained
strategy of prudent acquisitions and new center development. While the
resumption of significant acquisition activity is contingent upon the
aforementioned strategy, the Company is continually pursuing the development of
new imaging sites which complement the Company's network strategy.
The Company was incorporated in Delaware in 1993. The Company's executive
offices are located at 777 S. Flagler Drive, West Palm Beach, Florida 33401, its
telephone number is (561) 832-0006/(800) 7-USDLAB and its web site is at
WWW.USDL.COM. Unless the context otherwise requires, all references to the
"Company" include US DIAGNOSTIC INC. and its subsidiaries.
RECENT DEVELOPMENTS
On March 30, 1998, the Company entered into a definitive agreement to
sell the Company's mobile subsidiary, Medical Diagnostics, Inc. ("MDI"), to
Alliance Imaging Inc. for $35.6 million in cash less debt to be assumed of
approximately $6.5 million. The sale, which is subject to Hart-Scott-Rodino
clearance, is expected to close in May 1998. The proceeds of the sale will be
used to reduce the Company's debt and to bolster the Company's cash reserves.
See "Management's Discussion and Analysis of Financial Condition and Results of
Operations". Management believes that mobile imaging operations do not conform
with the Company's core business of fixed site MRI and multi-modality imaging
centers.
For information on asset impairment losses recorded during the quarter
ended December 31, 1997, see Notes 2 and 5 of the Notes to Consolidated
Financial Statements.
STRATEGY
During 1995 and 1996, the Company grew primarily through acquisitions of
Facilities from independent owners. In 1997, despite a significant decrease in
acquisition activity due to constraints on the Company's financial resources and
the need to consolidate prior acquisitions, the Company maintained its position
as the leading provider of outpatient diagnostic imaging and related services in
the United States based upon the number of facilities owned and operated. The
Company expects to continue to integrate its Facilities and to strengthen its
presence in existing markets. The Company expects to accomplish these objectives
by utilizing a multi-faceted strategy for internal and, when appropriate in the
future, for external growth as follows:
ACHIEVE OPERATING EFFICIENCIES. The Company generally utilizes its
management expertise and systems to operate Facilities which previously lacked
professional management. The Company consolidates certain aspects of operations,
such as accounting, administration, billing, collections, marketing and
purchasing, and believes that it can realize significant economies of scale. By
rendering support and management functions, the Company seeks to enable the
physicians providing services at the Facilities to spend more time focusing on
patient care, quality control and marketing, thereby increasing the utilization
rate of the Company's diagnostic equipment which should in turn positively
impact revenue favorably. In addition, the Company has implemented a significant
reduction in non-essential staff in the first quarter of 1998 (see "Employees")
and continues to focus on improving operating efficiencies Company-wide.
ENHANCE MANAGEMENT INFORMATION SYSTEMS. In order to assimilate and
effectively manage the Company's rapid growth, the Company has allocated $9.5
million towards the development of a state-of-the-art information system, of
which $ 8.3 million has already been invested, designed to implement a
3
<PAGE>
regional consolidation of its billing and collection operations. The new
information system, when fully implemented, is expected to allow on-line access
to its Facilities nationwide. See "Management's Discussion and Analysis of
Financial Condition and Results of Operations".
ACQUIRE ADDITIONAL IMAGING CENTERS. During 1997, the Company significantly
decreased its acquisition activity in order to integrate its Facilities and to
focus on its core operations, and, in part, due to an inability to obtain new
financing for acquisitions. In the past, the Company generally acquired
Facilities from: (i) owner/operators which may not have been in compliance with
regulations restricting referring physician ownership; (ii) owner/operators
seeking management expertise, access to managed care contracts and/or other
resources; and (iii) established companies which already owned several
Facilities within a concentrated region, and anticipates doing so again if its
financial condition permits. In addition, the Company has entered into joint
ventures with hospitals or other entities which desire access to diagnostic
imaging technologies but lack sufficient financial or managerial resources. To
date, the Company has evaluated only a fraction of the potential acquisition
candidates in the industry and intends to pursue additional acquisition
opportunities utilizing these strategies when and as it commences acquisition
activity in the future. See "Management's Discussion and Analysis - Liquidity
and Capital Resources".
CONTRACT WITH MANAGED CARE PROVIDERS. The Company actively pursues
contractual arrangements with managed care organizations. The Company believes
that third-party payors will increasingly prefer to contract for service on a
national or regional basis, and that the Company's development of a network of
centers will assist it in obtaining such contracts on favorable terms. Senior
management of the Company actively markets the Company's services to
administrators of managed care organizations in regions where the Company
operates Facilities. The Company has appointed a Vice President of Managed Care
to lead these efforts.
UPGRADE EXISTING MEDICAL TECHNOLOGIES. The Company offers state-of-the-art
diagnostic imaging and therapeutic technologies at many of its Facilities. After
acquisition of a Facility, the Company generally upgrades the MRI, CT, and
nuclear medicine equipment at its locations, resulting in improved image quality
and increased referring physician satisfaction. The Company also has installed
new high quality "Open MRI" equipment at certain locations to accommodate a
substantial number of patients who would otherwise forego this procedure due to
obesity or claustrophobia. In addition, the Company is adding new modalities and
procedures at most of its Facilities. Most of the new technologies are designed
to enhance the Company's revenue mix and shorten examination times, resulting in
increased capacity and profitability.
EXPAND SERVICE OFFERINGS WITH COMPLEMENTARY MEDICAL PROCEDURES. The
Company is developing medical services that are complementary to its core
imaging operations. These include: (i) pain management which is performed by
anesthesiologists to reduce patients' pain and possibly avoid the need for
surgery; (ii) bone densitometry which is a specialized x-ray procedure that
precisely quantifies bone density at the spine, femur and other skeletal sites
for diagnosis and treatment of osteoporosis; and (iii) cardio-diagnostic
medicine, including nuclear cardiology.
PROFESSIONAL MARKETING. In order to expand referral sources, the Company
provides marketing training and materials to Facility personnel in order to
market to area physicians and third-party payors such as managed care
organizations. Most Facilities have previously focused their marketing efforts
only on physicians and not managed care organizations. The Company utilizes a
variety of marketing techniques in the communities where it does business,
including meetings between the Facility administrators or account executives and
referring physicians and/or their staff, financial and social seminars, mailings
of technical case studies and clinical articles.
4
<PAGE>
PROVIDE MANAGEMENT SERVICES TO UNAFFILIATED CENTERS. In addition to
providing management services to its own Facilities, the Company offers its
management services to independent diagnostic centers, private radiology
practices and hospital radiology practices. The Company believes that its
expertise may potentially be useful for practices that have not had the benefit
of professional management. Each client is able to contract for individual or a
full range of services, including accounting, billing, collections, debt
consolidation, management information systems, purchasing and human resources.
The Company prices its services using a number of methods, including
fee-for-services, percentage of revenue or savings, capitation or on a project
basis.
PARTNERING WITH HOSPITALS AND RADIOLOGY GROUPS. Currently, the Company has
several joint ventures to provide services at hospitals with large companies
such as Columbia/HCA, Tenet Healthcare and Universal Health Services. Hospitals
are increasingly moving towards outsourcing various components of their
operations. The Company believes opportunities exist to enter into agreements
with many hospitals to manage their in-patient radiology departments.
INDUSTRY OVERVIEW
Total annual spending on diagnostic imaging services in the United States
is estimated to be between $56 billion and $70 billion. While 70% of this
spending is done in hospital settings, a significant share of the market is
commanded by the nation's 2,200 outpatient testing facilities, especially in
relation to the roughly $10 billion subsector of advanced imaging services,
which includes MRI and CAT scans.
Payment for services comes primarily from third-party payors, such as
private insurers (traditional indemnity and Blue Cross/Blue Shield plans),
managed health plans (HMOs, PPOs), government payors (Medicare, Medicaid), and
state-run worker's compensation programs. Some centers have significant
relationships with attorneys specializing in personal injury litigation.
Typically, large third-party payors, especially managed care programs and
Medicare/Medicaid, demand significant discounts from the list prices paid under
direct-bill circumstances.
The number of non-hospital-affiliated imaging centers has grown due to a
number of factors. First, when Congress reformed Medicare in 1983 by putting
strict controls on inpatient reimbursement, this led to the expansion of all
types of freestanding outpatient services, including outpatient surgery and
imaging centers. Second, the use of MRI, CT and other equipment became more
prevalent due to the quality and quantity of diagnostic information,
technological improvements and increased government and third-party
reimbursement. Although MRI was developed in the late 1970s, it was not approved
for Medicare reimbursement until 1984. Ultrasound and low-dose mammography
technology improved in the late 1980s. New technologies and procedures continue
to be developed, although some, such as positron emission tomography ("PET")
scanners, are relatively expensive and are not considered cost-effective for
most procedures. Third, the number of hospital and physician joint ventures
increased in the 1980s as hospitals were eager to minimize their financial
exposure for expensive equipment and physicians were seeking investments at a
time when traditional tax sheltered investments were being eliminated or were
less economic. Thus, between 1984 and 1991, the number of outpatient imaging
centers in operation in the U.S. increased from roughly 700 to over 2,000.
5
<PAGE>
The industry generally suffered setbacks in 1993 as utilization levels
generally stabilized and reimbursement per test declined sharply. Utilization
rates stopped growing primarily for three reasons: (i) the threat of sweeping
government health care reform put expensive procedures under increased scrutiny;
(ii) market forces - arriving in the form of managed care which also discouraged
providers from ordering all but absolutely necessary tests; and (iii) the
extension in 1993 of federal laws (the "Stark Laws"), prohibiting the referral
by physicians of Medicare and Medicaid patients to entities with which such
referring physicians have a financial relationship (either an ownership interest
or compensation arrangement), to referrals for the kinds of covered diagnostic
imaging services provided by the Company at its Facilities. See "Regulation and
Government Reimbursement". Previously, these referral prohibitions had been
applicable only to Medicare-covered clinical laboratory services. Since the
early 1990s, the total installed base of MRI systems has remained relatively
flat although the total number of procedures has increased.
In 1996, Medicare reimbursement for MRI procedures increased approximately
1%-2% over 1995 levels - the first increase in at least four years. In January
1998, Medicare reimbursement for diagnostic procedures increased an additional
1%-2%; however, the Health Care Financing Administration ("HCFA") is considering
imposing reductions in reimbursement beginning January 1999 over a four-year
phase-in period. See "Regulation and Government Reimbursement". Public HMOs,
which have suffered from declining margins, have indicated that their corrective
actions will more likely take the form of more rational premium pricing than of
further pressure on providers' fee-for-service reimbursement levels. The Company
believes that as managed care becomes more prevalent, further decreases in the
average reimbursement per test will be mostly attributable to payor mix shifts
to increased managed care business which generally have lower reimbursement
rates than commercial insurance payors. There is also the potential for a
softening pricing environment as companies become more discerning in negotiating
managed care contracts and as the industry continues to consolidate.
ACQUISITIONS
Prior to 1997, the Company grew rapidly by acquisition. As noted
previously, the Company's acquisition activity substantially decreased in 1997.
While the Company anticipates a return to a prudent acquisition plan in 1998,
there can be no assurances as to whether and when such activity will commence.
In evaluating an acquisition candidate, the Company analyzes a number of
strategic characteristics including the mix of services provided, the nature of
services demanded in the market versus those currently provided by the
candidate, the presence and strength of local competition, net revenues,
operating income, insurance reimbursement and historical referral and volume
patterns. The Company believes that there are and will continue to be many
attractive acquisition opportunities because imaging center operators are
finding it more difficult to compete independently as managed care becomes more
prevalent.
6
<PAGE>
The following is a list of the Company's completed acquisitions and centers
opened:
<TABLE>
<CAPTION>
DATE NAME LOCATION BUSINESS OWNERSHIP %
- ---- ----------------------------------- ---------------- --------------------- -----------
<S> <C> <C> <C> <C>
6/94 Computerized Medical Imaging Center Sherman Oaks, CA Multi-Modality Imaging 56.9
8/94 Columbus Diagnostic Center Columbus, GA Multi-Modality Imaging 100
1/95 Santa Fe Imaging Center Santa Fe, NM Multi-Modality Imaging 100
2/95 Laborde Diagnostic Center Lafayette, LA Multi-Modality Imaging 80
Southern Diagnostic Center Lafayette, LA Multi-Modality Imaging 80
2/95 Community Radiology of Virginia Bluefield, VA Multi-Modality Imaging 100
Princeton, WV Multi-Modality Imaging 100
7/95 Salisbury Imaging Center Jacksonville, FL Multi-Modality Imaging 50
8/95 Orange Park Diagnostic Center Jacksonville, FL Multi-Modality Imaging 50
9/95 San Francisco MRC San Francisco, CA MRI 100
10/95 Advanced Medical Imaging Center Montgomery, AL Multi-Modality Imaging 100
11/95 FutureCare Affiliates, Inc. 100
Valley Presbyterian MRC Van Nuys, CA MRI 56.9
12/95 Modesto Imaging Center Modesto, CA Multi-Modality Imaging 100
4/96 US Cancer Care Inc. Modesto, CA Radiation Therapy Centers 50.1
6/96 US Imaging Houston, TX Imaging Chain 100
5/96 Wilkes Barre Imaging (2) Wilkes Barre, PA MRI 60
7/96 Owner Diagnostic California MSO 67.5
7/96 Allegheny MRI Pittsburgh, PA Imaging Chain 100
6/96 South Coast Radiologists Coos Bay, OR Multi-Modality Imaging 100
6/96 Heights Imaging Center Haddon Heights, NJ Multi-Modality Imaging 100
7/96 MediTek Health Corp. Miami, FL Imaging Chain 100
7/96 Ft. Lauderdale Regional MRI Center Ft. Lauderdale, FL MRI Center 100
8/96 LINC Imaging California Imaging Chain 100
8/96 Integrated Health Concepts Houston, TX Imaging Chain 70
9/96 Alliance Group International San Francisco, CA Physician/Imaging Hospital 50.1
Management Company
11/96 San Antonio Diagnostic Imaging San Antonio, TX Imaging Chain 100
10/96 Medical Marketing Development New York Imaging Management Company 100
10/96 MRI of Monmouth Tinton Falls, NJ MRI Center 100
10/96 Narrows MRI Brooklyn, NY MRI Center 100
10/96 Metropolitan Imaging Garden City, NY Multi-Modality Center 100
10/96 Grammercy MRI New York, NY MRI Center 100
11/96 Dayton Medical Imaging Dayton, OH Imaging Chain 100
11/96 Lee Imaging (3) New York, NY Nuclear Imaging Chain 100
11/96 MICA San Diego, CA Imaging Chain - Fixed and Mobile 100
2/97 Medical Diagnostics, Inc. (1) Boston, MA Imaging Chain - Fixed and Mobile 100
8/97 Valley Open MRI (2) Sherman Oaks, CA MRI 100
<FN>
- -----------------
(1) A contract for the sale of Medical Diagnostics, Inc. was signed on March
30, 1998. See "Recent Developments".
(2) These centers were opened directly by the Company.
(3) During 1996, the Company acquired 80%. During 1997, the Company acquired
the remaining 20%.
</FN>
</TABLE>
7
<PAGE>
The Company financed its acquisitions with cash, notes, equipment leases,
assumption of indebtedness, public and private offerings of debt and equity
securities and combinations of the foregoing and expects to finance future
acquisitions, to the extent undertaken, similarly. The Company generally
acquired at least an 80% interest in a center, but in certain cases only
purchased a majority interest. In certain of the acquisitions, a portion of the
consideration was held in escrow pending the attainment of certain agreed upon
revenue or earnings targets of the acquired Facility. The Company also entered
into long-term radiology agreements with radiologists who were owners of centers
purchased by the Company. In connection with certain acquisitions, the Company
entered into property leases at fair market value for the facility, many of
which are with the physician partnership that was the seller of the center.
IMAGING OPERATIONS
Diagnostic imaging services are performed on an outpatient basis by
experienced radiological technicians. After the diagnostic procedures are
completed, the images are reviewed by radiologists who have contracted with the
Company. The radiologists prepare a report of the tests and their findings,
which are delivered to the referring physician. Additionally, upon request, a
report of any critical abnormality, or "stat report," is provided by phone as
soon as the test is completed and evaluated.
Each of the Company's Facilities have agreements with radiologists as
independent contractors under long-term agreements to provide all radiology
services to the Facilities. Radiologists' compensation ranges between 8%-21% of
net collections attributable to radiology services performed by the radiologist.
The interpreting physicians are board-certified or board eligible specialists in
radiology, orthopedics, cardiology or neurology, as appropriate. The Company
currently operates a majority of the Facilities out of four regional billing
offices which bill and collect both for technical services and professional
services of interpreting physicians at the Facilities. A few Facilities bill and
collect independently on individual systems.
Imaging revenues are dependent to a large extent upon the acceptance of
outpatient diagnostic imaging procedures as covered benefits under various
third-party payor programs. In order to receive reimbursement for these
services, payment must be approved by private insurers or the Medicare and
Medicaid reimbursement programs. Although the Company intends to continue its
participation in such reimbursement programs, there can be no assurance that its
imaging procedures will continue to qualify for reimbursement. See "Industry
Overview".
CLIENTS AND PAYORS
The Company is highly dependent on referrals from physicians who have no
contractual obligation or economic incentive to refer patients to the Company's
Facilities. Most Facilities currently receive referrals from several hundred
physicians. If a sufficiently large number of physicians elected at any time to
stop referring patients to the Company, it would have a material adverse effect
on the Company's revenues and results of operations. In particular, due to the
potential for disruption of the physician relationship in connection with the
assumption of control of a Facility, there can be no assurance that the Company
will retain all of the business conducted by that Facility at the time of its
acquisition.
In 1997, revenues from conventional indemnity insurance carriers accounted
for approximately 22% of the Company's revenues, Medicare and Medicaid accounted
for approximately 19% of revenues, managed care accounted for approximately 35%
of revenues and the remainder was derived directly from patients and workers'
compensation cases.
8
<PAGE>
The Company is a party to over 1,000 managed care contracts which require
it to provide services on a fixed-fee for service basis. All Facilities are
attempting to obtain additional managed care contracts.
During the fourth quarter of 1996, the Company began to consolidate
billing and collections out of four regional offices utilizing a new computer
and software information system. Substantially all of the centers initially
targeted to be converted onto the new system were completed by December 31,
1997. It is anticipated that the remaining targeted centers will be completed by
mid-1998 upon resolution of operational issues. Some Facilities have experienced
what appears to be a temporary cash collection reduction during the phase-in of
the new system due to the complexity of collecting the accounts receivable on
the prior computer systems while installing the new billing and collection
system. In addition, the initial efficiency of the new centralized system was
adversely impacted by various training and other operationally related problems.
Aggressive measures have been, and continue to be taken, to collect accounts
receivable from the predecessor billing and collection systems of various
Facilities.
COMPETITION
The market for diagnostic imaging services is highly competitive. The
market is highly fragmented with over 2,200 outpatient diagnostic imaging
centers nationwide and no dominant national imaging services provider.
Competition varies by market and is generally higher in larger metropolitan
areas where there is likely to be more Facilities and more managed care
organizations putting pricing pressure on the market. The Company competes with
larger healthcare providers, such as hospitals, as well as other private clinics
and radiology practices that own diagnostic imaging equipment. Competition often
focuses on physician referrals at the local market level. Successful competition
for referrals is a result of many factors, including participation in healthcare
plans, quality and timeliness of test results, type and quality of equipment,
facility location, convenience of scheduling and availability of patient
appointment times.
REGULATION AND GOVERNMENT REIMBURSEMENT
OVERVIEW. The healthcare industry is highly regulated and is undergoing
significant change as third-party payors, such as Medicare and Medicaid, health
maintenance organizations and other health insurance carriers, increase efforts
to control the cost, utilization and delivery of healthcare services.
Legislation has been proposed or enacted at both the federal and state levels to
regulate healthcare delivery in general and radiology services in particular.
The Company believes that reductions in reimbursement for Medicare and Medicaid
services may be implemented from time to time, which may lead to reductions in
the reimbursement rates of other third party payors as well. The Company cannot
predict the effect healthcare reforms may have on its business, and there can be
no assurance that such reforms will not have a material adverse effect on the
Company's operations. All of the Company's Facilities are subject to
governmental regulation at the federal, state and local levels.
Proposed Medicare rules which were published in the June and October 1997,
respectively, require the development of a resource-based system for determining
practice expense relative value units (RVU's). The final rule development has
been delayed one year until January 1, 1999, with the proposed rules to be
published on July 31, 1998. The delay in implementation was mandated by Congress
to allow for a gathering of additional information, evaluation of costs and a
new recommendation by HCFA. It is uncertain whether HCFA will modify the October
1997 proposed rules by suggesting higher or lower rates. The implications of
this proposal, if left unchanged, for the diagnostic imaging technical component
services would result in reductions in reimbursement; however, HCFA is
considering a
9
<PAGE>
four-year phase-in period beginning January 1999. The final outcome to the
proposed fee restructuring and the impact on diagnostic facilities, and on the
Company, cannot be predicted at this time.
REGULATION OF OUTPATIENT IMAGING SERVICES. The operation of outpatient
imaging centers requires a number of licenses, including licenses for technical
personnel and certain equipment. Licensure requirements may vary somewhat from
state to state in the states in which the Company does business. The Company
believes that it is in material compliance with applicable licensure
requirements. The Company further believes that diagnostic testing will continue
to be subject to strict regulation at the federal and state levels and cannot
predict the scope and effect thereof.
Diagnostic imaging centers performing mammography services must meet
federal, and in some jurisdictions, state standards for quality as well as
certification requirements. Under regulations issued by the Federal Food and
Drug Administration ("FDA") pursuant to the Mammography Quality Standards Act of
1992 ("MQSA"), all mammography Facilities are required to be accredited by an
approved non-profit organization or state agency. Pursuant to the accreditation
process, each Facility providing mammography services must: undergo an annual
mammography facility physics survey; be inspected annually and pay an annual
inspection fee; meet qualification standards for interpreting physicians,
mammography technologists, and medical physicists; meet certification
requirements for adequacy and training and experience of personnel; meet quality
standards for equipment and practices; and meet various requirements governing
record keeping of patient files. Compliance with these standards is required to
obtain payment for Medicare services and to avoid various sanctions, including
monetary penalties, or suspension of certification. Although all of the
Company's Facilities which provide mammography services are currently accredited
by the Mammography Accreditation Program of the American College of Radiology
and the Company anticipates continuing to meet the requirements for
accreditation, the withdrawal of such accreditation could result in the
revocation of certification. Congress has extended Medicare benefits to include
coverage of screening mammography subject to prescribed quality standards
described above. The regulations apply to diagnostic mammography and image
quality examination as well as screening mammography.
REIMBURSEMENT FOR RADIOLOGY SERVICES. In general, Medicare reimburses
radiology services under a physician fee schedule which covers services provided
not only in a physician's offices, but also in freestanding Facilities, portable
X-ray suppliers, hospitals and other entities. The scheduled amount is based on
a resource-based relative value scale, recognizing three separate components of
the physician's services: professional, technical and malpractice. For radiology
there are separate Medicare scheduled amounts for the professional component of
a service or procedure (i.e., the physician's time) and the technical component
of the service or procedure (i.e., services and supplies necessary to perform
the procedure).
Congress and the U.S. Department of Health and Human Services have taken
various actions over the years to reduce reimbursement rates for radiology
services and proposals to reduce rates further are anticipated. As noted above,
there have been many proposals discussed within the last few years to further
modify reimbursement. The Company is unable to predict which, if any, proposals
will be adopted. Any reductions in Medicare reimbursement for radiology services
could have a material adverse effect on the Company.
REGULATION OF RADIOLOGY OWNERSHIP; FRAUD AND ABUSE. Medicare payment rules
discourage physicians from maintaining an investment interest in radiology
operations. The Omnibus Budget
10
<PAGE>
Reconciliation Act of 1989 ("OBRA 89") contains provisions which, effective as
of January 1, 1992, prohibit physicians from referring Medicare or Medicaid
patients to clinical laboratories in which the physician has an economic
interest. In 1993, Congress extended the physician self-referral prohibition,
effective January 1, 1995, to entities providing other designated health care
services, including radiology or other diagnostic services, including MRI, CAT
scans and ultrasound services, and radiation therapy services. Violations of
these provisions (collectively known as the "Stark Laws") may result in denial
of payments for the service, an obligation to refund payment for the service,
payment of civil monetary penalties and/or exclusion from the Medicare, Medicaid
and other state health care programs.
The Anti-Fraud and Abuse Amendments to the Social Security Act prohibit
the solicitation, payment, receipt or offer, directly or indirectly, of any
remuneration for the referral of Medicare or Medicaid patients or for the
provision of services, items or equipment which may be covered by the Medicare
or Medicaid programs. Violations of these provisions may result in civil and
criminal penalties and exclusion from participation in the Medicare and Medicaid
programs.
In addition to federal restrictions, which are generally applicable to
Medicare, Medicaid and other state health care patients, a number of states in
which the Company operates Facilities have enacted prohibitions against
physicians referring patients to entities with which they have a financial
relationship (an ownership interest or compensation arrangement). Such state
laws generally apply to all patients, not just participants in the Medicare and
Medicaid programs. The Company has structured its acquisitions of
physician-owned ventures and ongoing relationships with physicians in a manner
which it believes does not raise significant issues under federal or state
anti-kickback and self-referral regulations.
CORPORATE PRACTICE OF MEDICINE; FEE SPLITTING. The operation of the
Facilities may be subject to the laws of certain states which prohibit the
practice of medicine by non-physicians and/or the splitting of fees between
physicians and non-physicians. The Company believes its operations are conducted
in material compliance with existing applicable laws relating to the corporate
practice of medicine and fee splitting. In response to such laws, in certain
states, the Company may operate Facilities pursuant to a management agreement
with a physician group rather than operating the Facility directly and
contracting with the physicians for professional medical services.
INFECTIOUS WASTES. The Company is also subject to licensing and regulation
under federal and state laws relating to the handling and disposal of medical
specimens, infectious and hazardous waste and radioactive materials as well as
to the safety and health of laboratory employees. The sanctions for failure to
comply with these regulations may include denial of the right to conduct
business, significant fines and criminal penalties, any of which, if imposed,
could have a material adverse effect on the Company. The Company believes that
it is in substantial compliance with all applicable laws and regulations
relating to these materials.
INSURANCE
The Company could be subject to legal actions arising out of the
performance of its diagnostic imaging services. Damages assessed in connection
with, and the costs of defending, any such actions could be substantial. The
Company currently maintains liability insurance which it believes is adequate
for its present operations. There can be no assurance that the Company will be
able to continue or increase such coverage at an acceptable cost, or that the
Company will have other resources sufficient to satisfy any liability or
litigation expense that may result from any uninsured or underinsured claims.
The Company also requires all of its affiliated physicians to maintain
malpractice and other liability
11
<PAGE>
coverage. In the event that a claim exceeds available coverage, the Company's
financial condition and results of operations could be adversely and materially
affected.
EMPLOYEES
In February 1998, the Company reduced its workforce by approximately 137
employees. The Company does not currently anticipate additional significant
staff reductions. As of March 31, 1998, the Company had approximately 1,312 full
time and 175 part time employees, none of whom is represented under union
contracts or other collective bargaining arrangements. The Company considers its
relations with its employees to be good.
ITEM 2. PROPERTIES.
During 1997, the Company maintained its executive offices, corporate
accounting and certain administrative and other operations in West Palm Beach,
Florida occupying approximately 13,400 square feet of leased space.
Approximately 9,200 square feet was under lease and the balance was month to
month. The lease has an annual rent of approximately $532,000 and expires in
2009. Due to the Company's rapid growth over the past few years, the amount of
space at this facility became insufficient, and effective January 1998, the
Company entered into a 10 year lease for up to approximately 23,200 additional
square feet of office space at a separate location in West Palm Beach, Florida,
where the Company has relocated its corporate accounting and certain other
administrative operations. Annual rent on this new facility will be
approximately $283,000. The Company is currently leasing 11,600 square feet at
this location and, pursuant to the contract, the Company will further increase
the size of the new office facilities by up to the full 23,200 square feet
beginning in March 1999 under similar terms. Concurrent with the leasing of the
new office facilities in January 1998, the Company reduced the amount of space
used at its executive offices on a month to month basis by approximately 4,200
feet, resulting in a reduction in annual lease expense for the executive offices
of approximately $168,000.
The Company operates imaging centers that range in size from approximately
800 to 21,600 square feet. The Company also has 4 regional billing and
operational centers, with leases expiring between 1997 and 2006. The aggregate
lease expense in 1997 for such leases was approximately $1.5 million.
The Company believes that its current facilities are in adequate condition
and otherwise suitable for its current operations.
ITEM 3. LEGAL PROCEEDINGS.
In January 1997, six separate class action lawsuits were filed against the
Company and certain officers, directors and other parties alleging failure to
make disclosure regarding the background of Keith Greenberg, who had provided
consulting services to the Company through Coyote Consulting and Financial
Services, LLC ("Coyote Consulting"). Four of the lawsuits have been dismissed
and the two remaining suits have been heard in the United States District Court
for the Southern District of Florida, and have been settled in principle
pursuant to a Memorandum of Understanding (the "Memorandum") dated July 31, 1997
and a more detailed Stipulation of Settlement (the "Stipulation") filed with the
Court on March 6, 1998. The Memorandum and Stipulation include a denial of any
wrongdoing or liability by both the Company and the individually named
defendants. In accordance with the terms of these documents, the parties agreed
to settle all pending class action claims against the Company (including
additional claims based on alleged misstatements of financial condition) for
$5.9 million, payable $588,000 within ten days after signing; an additional $1.5
million ten days after Court
12
<PAGE>
approval of the proposed notice advising the class of the settlement; and the
remaining $3.8 million no later than twenty-five days before a final hearing for
approval of the settlement. The first payment was made by the Company as
required on August 11, 1997. The second payment became due and was made on April
4, 1998 and the final payment is now due in late May 1998. The settlement is
subject to a court approval process expected to take several months. The
payments, when made, are to be deposited into an interest-bearing account to be
held in escrow by plaintiffs' counsel, pending court approval. The Company
reached an agreement with its insurance carrier whereby the insurer has
contributed $1.0 million toward the Company's settlement obligation in full
satisfaction of its director and officer liability insurance policy obligations.
In addition, the Company's former CEO, Jeffrey Goffman, has contributed $850,000
cash and $150,000 in debt forgiveness as described in more detail in Note 19 of
the accompanying Notes to Consolidated Financial Statements. The Company is
currently in negotiations in which it is seeking additional contribution from
other third parties. There can be no assurance that the Company will be
successful in these negotiations. During the quarter ended June 30, 1997, the
Company recorded a provision for settlement of lawsuits in the amount of $4.9
million, comprising the $5.9 million settlement, net of the $1.0 million
contribution from the insurance company. During the quarter ended September 30,
1997, a credit of $1.0 million was recorded in Settlement with Former Chief
Executive Officer to reflect the contribution from Mr. Goffman.
In addition to the class actions described above, two suits have been
filed against the Company by sellers of diagnostic imaging centers who received
the Company's Common Stock in partial payment of the purchase price for their
centers and who allege that undisclosed facts regarding Keith Greenberg's
background were material to their decision to sell. In connection with the first
of these actions (Centre Commons MRI Ltd., et. al. v. U.S. Diagnostic et. al.),
in the United States District Court for the Western District of Pennsylvania,
the sellers of multiple centers in Pennsylvania seek to compel the Company to
repurchase approximately 750,000 shares of its common stock at a price of
$12.125 per share and also allege that the Company's failure to register such
shares under the Securities Act of 1933, pursuant to a written contract,
diminished their value. Even if registered, the shares were subject to limited
releases from lock-up until July 1997 when they became tradable pursuant to Rule
144 without the need for registration. In the second such suit (Sanders et. al.
v. US Diagnostic, et. al.), in the United States District Court for the Eastern
District of New York, four participants in limited partnerships which sold the
Company three imaging centers in New York seek to recover damages of up to $6
per share for approximately 90,000 shares of the Company's Common Stock. The
Company is vigorously defending both suits but there can be no assurances that
the Company will prevail.
In September 1992, Medical Diagnostic, Inc. ("MDI") and its affiliate
Greater Springfield MRI Limited Partnership ("Springfield") (through its general
partner, Western Massachusetts Magnetic Resonance Services, Inc. a subsidiary of
MDI ("WMMRS")), filed suits against Raytel Corporation, Inc. and certain other
parties (collectively, the "Raytel Defendants") seeking a declaration, damages
and equitable relief against the Raytel Defendants. Various counterclaims were
filed against MDI seeking up to $8 million in damages and injunctive relief. The
Company acquired MDI (of which Springfield and WMMRS are direct or indirect
subsidiaries or affiliates) in February 1997. As part of this acquisition the
seller, Advanced NMR Systems, Inc., agreed to indemnify the Company and MDI for
losses incurred in connection with the foregoing litigation. The litigation,
which was heard in the State Superior Court in California, was settled at no
cost to the Company in October 1997.
The Company is currently involved in litigation related to its acquisition
of stock in Integrated Health Concepts, Inc. ("IHC") in August 1996. In March
1997, litigation was commenced in state court in Harris County, Texas to
determine the respective stock interests of the Company, Don Ballard, Dr.
13
<PAGE>
Mohammed Athari and a key man trust which, together, comprise all of IHC's
shareholders. In June 1997, the Court issued a ruling upholding the Company's
position that it owns 70% of IHC's stock. Subsequently, IHC appointed a new
Board of Directors which terminated Mr. Ballard's employment as President of
IHC. Mr. Ballard filed additional claims against IHC and the Company alleging
that they had breached fiduciary duties owing to him and that they were
obligated to pay him more than $1.0 million based upon termination of his
employment, to provide him with $250,000 of Company Common Stock, and to
repurchase his IHC stock (and that of a key man trust established for his
benefit) for its fair market value which Mr. Ballard contended was approximately
$8 million. The Company and IHC have vigorously contested such claims and have
asserted their own claims against Mr. Ballard aggregating approximately $1.3
million. The matter was tried during October 1997 and is currently under
consideration by the Court. There can be no assurances that the Company will
prevail. In March 1998, Mr. Ballard filed a request for additional trial
proceedings contending that since the original trial in October 1997, the
Company has denied his rights as a minority shareholder of IHC. The claims
asserted against IHC and the Company by Dr. Mohammed Athari were fully settled
and resolved without additional payments by either IHC or the Company.
In 1997 the Securities and Exchange Commission ("SEC") initiated an
investigation into the Company's former relationship with Coyote Consulting and
Keith Greenberg, and the adequacy of the Company's disclosure concerning that
relationship. The inquiry appears to be focused on whether the disclosures with
respect to Mr. Greenberg and Coyote Consulting were in compliance with the
federal securities laws. The Company cooperated fully with the SEC.
The Company could be subject to legal actions arising out of the
performance of its diagnostic imaging services. Damages assessed in connection
with, and the cost of defending, any such actions could be substantial. The
Company maintains liability insurance which it believes is adequate for its
present operations. There can be no assurance that the Company will be able to
continue or increase such coverage or to do so at an acceptable cost, or that
the Company will have other resources sufficient to satisfy any liability or
litigation expense that may result from any uninsured or underinsured claims.
The Company also requires all of its affiliated physicians to maintain
malpractice and other liability coverage.
The Company is also a party to, and has been threatened with, a number of
other legal proceedings in the ordinary course of business. While it is not
feasible to predict or determine the outcome of these matters, and although
there can be no assurances, the Company does not anticipate that the ultimate
disposition of any such proceedings will have a material adverse effect on the
Company.
14
<PAGE>
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY-HOLDERS.
At the Company's 1997 Annual Meeting of Stockholders held on November 5,
1997, the stockholders of the Company voted upon and elected the following
directors and approved and adopted the following proposals:
(A) DIRECTOR NOMINEE VOTES CAST FOR VOTES WITHHELD
---------------- -------------- --------------
C. Keith Hartley 18,714,763 1,408,690
Laurans A. Mendelson (1) 18,558,765 1,564,688
Joseph A. Paul 18,520,131 1,603,322
Gordon C. Rausser 18,551,931 1,571,522
L. E. Richey 18,796,781 1,326,672
(B) Approved and ratified an amendment to the Company's 1995 Long-Term
Incentive Plan to increase the number of authorized shares of the
Company's Common Stock available for grant thereunder from 3,000,000
to 4,700,000 shares (5,284,867 votes were cast for this matter,
2,997,281 votes were cast against this matter and there were 174,587
abstentions and broker non-votes).
(C) Approved and ratified the appointment of Arthur Andersen LLP as the
Company's independent accountants for the fiscal year 1997 (19,604,757
votes were cast for this matter, 451,124 votes were cast against this
matter and there were 67,572 abstentions and broker non-votes).
(1) Resigned on December 1, 1997. On January 20, 1998, Michael
O'Hanlon, the Chief Executive Officer of DVI, Inc., an affiliate
of DVIBC and DVIFS, was elected to the Board of Directors of the
Company. DVIFS and DVIBC are lenders to the Company. See Note 6
of Notes to Consolidated Financial Statements.
15
<PAGE>
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.
The Company's Common Stock has traded under the symbol USDL on the NASDAQ
National Market since October 9, 1995 and prior to that on the NASDAQ Small Cap
Market since October 20, 1994. The following table sets forth the high and low
bid information for the Company's Common Stock for each quarter within the two
years ended December 31,1997 as reported by NASDAQ. These prices do not reflect
retail mark-ups, markdowns or commissions and may not represent actual
transactions.
HIGH LOW
------ -----
1996
----
January 1 through March 31, 1996............. 9 6
April 1 through June 30, 1996................ 14 3/4 7
July 1 through September 30, 1996............ 13 5/8 8 3/8
October 1 through December 31, 1996.......... 13 3/4 7 7/8
1997
----
January 1 through March 31, 1997............. 13 3/8 5 7/8
April 1 through June 30, 1997................ 9 1/8 5
July 1 through September 30, 1997............ 9 7/8 6 3/8
October 1 through December 31, 1997.......... 8 3 3/32
The number of record holders of the Company's Common Stock as of April
10,1998 was approximately 294.
The Company has never paid a cash dividend on its Common Stock and
anticipates that for the foreseeable future any earnings will be retained for
use in its business and, accordingly, does not anticipate the payment of cash
dividends. The Company has outstanding debt which prohibits the payment of
dividends by the Company without the consent of the lender.
As the Company previously disclosed, on July 3, 1997 a NASDAQ Listing
Qualifications Panel determined that the Company was not in compliance with the
net tangible assets test for continued listing on the NASDAQ National Market
System, but determined after a hearing to grant the Company a waiver.
Accordingly, while the Company does not presently meet all of the NASDAQ's
continued listing criteria, the Company's securities remain listed on the NASDAQ
National Market System pursuant to the waiver. NASDAQ has informed the Company
that it will continue to monitor the Company's progress, and that it reserves
the right, in the event there is a material change in the Company's operational
or financial structure or character, to re-examine the appropriateness of the
waiver.
There can be no assurance that, if NASDAQ determines in the future that
the Company's net tangible asset waiver is no longer effective, the Company will
be able to meet the requirements for continued listing under NASDAQ's current
listing standards of $5 per share minimum bid price contained in the new
alternative listing standards (absent the occurrence of certain events such as a
reverse stock split).
16
<PAGE>
ITEM 6. SELECTED FINANCIAL DATA.
The selected financial data presented below summarizes certain historical
financial data and should be read in conjunction with the more detailed
financial statements of the Company and the notes thereto included elsewhere
herein. All prior-period earnings(loss) per share data have been restated to
reflect the requirements of Statement of Financial Accounting Standards No. 128,
"Earnings Per Share", which became effective for the year ended Decemer 31,
1997.
<TABLE>
<CAPTION>
FROM JUNE 17,
1993
FISCAL YEAR ENDED DECEMBER 31, (DATE OF
INCEPTION)
TO
DECEMBER
1997 1996 1995 1994 31,1993
----------- ----------- ---------- --------- ------------
(In thousands, except per share amount)
STATEMENT OF OPERATIONS DATA
- ----------------------------
<S> <C> <C> <C> <C> <C>
Net revenues $ 216,222 $ 102,061 $ 29,416 $ 5,082 $ 338
Income (loss) before extraordinary item (116,712) (6,331) 3,025 (640) (194)
Extraordinary item -- -- 306 -- --
Net income (loss) (116,712) (6,331) 3,331 (640) (194)
Basic earnings (loss) per common share
Income (loss) before extraordinary item (5.26) (.48) .70 (.48) (.29)
Extraordinary item -- -- .07 -- --
Net income (loss) (5.26) (.48) .77 (.48) (.29)
Diluted earnings (loss) per common share
Income (loss) before extraordinary item (5.26) (.48) .64 (.48) (.29)
Extraordinary item -- -- .06 -- --
Net income (loss) (5.26) (.48) .70 (.48) (.29)
Cash dividends declared per common share -- -- -- -- --
As of December 31,
1997 1996 1995 1994 1993
---------- ----------- ----------- --------- -------
(In thousands)
BALANCE SHEET DATA
- ------------------
Total assets $ 287,999 $ 339,023 $ 57,279 $ 13,892 $ 2,328
Total long-term obligations 186,818 117,070 21,065 2,929 --
</TABLE>
17
<PAGE>
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
Forward-Looking Statements and Associated Risks
Certain matters discussed herein are forward-looking statements made
pursuant to the safe harbor provisions of the Securities Litigation Reform Act
of 1995. These forward-looking statements are based largely on the Company's
expectations and are subject to a number of risks and uncertainties, including
but not limited to, economic, competitive, regulatory, growth strategies,
available financing, and other factors discussed elsewhere in this report and
the documents filed by the Company with the SEC. Many of these factors are
beyond the Company's control. Actual results could differ materially from the
forward-looking statements. In light of these risks and uncertainties, there can
be no assurance that the forward-looking information contained in this report
will, in fact, occur.
OVERVIEW
The Company did not commence operations until the completion of its first
acquisition in October 1993. The Company has historically grown through
acquisitions of diagnostic imaging centers and businesses. The Company's
operating performance is substantially dependent upon its ability to integrate
the operations of acquired facilities into the Company's infrastructure and
reduce operating expenses of acquired entities, its ability to deliver
equivalent service to clients immediately after an acquisition without
significant interruption or inconvenience and various other risks associated
with the acquisition of businesses, including expenses associated with the
integration of the acquired businesses. If the Company is unable to manage
growth effectively, the Company's operating results could be materially
adversely affected.
The Company reports revenue at the estimated net realizable amounts
from patients, third-party payors and others for services rendered including
estimated contractual adjustments under reimbursement agreements with
third-party payors. These adjustments are accrued on an estimated basis in the
period the related services are rendered and are adjusted in future periods as
final settlements are determined.
The Company's revenues and profitability may be materially adversely
affected by the current trend in the healthcare industry toward cost
containment, continuing governmental budgetary constraints, reductions in
reimbursement rates, changes in the mix of the Company's patients and other
changes in reimbursement for healthcare services, and other factors, which
may put downward pressure on revenue per scan. See also "Business--Clients and
Payors" and "Business--Regulations and Government Reimbursement".
RECENT DEVELOPMENTS
During the first quarter of 1998 the Company developed a strategy to
reduce debt and increase cash flows consisting of the following: (i) implement a
cost reduction plan which includes a significant reduction in nonessential staff
and other consolidation synergy, heretofore not applied. The aggregate reduction
of these employee-related expenses is expected to save approximately $5 million
annually; (ii) divest non-core assets and focus upon the Company's core
business. In addition to the MDI transaction described below, the Company is
currently reviewing other non-core assets and will pursue other such sales as
warranted; (iii) seek to refinance the Company's long term debt, and (iv) once
the first three
18
<PAGE>
steps have been accomplished, institute a sustained strategy of prudent
acquisitions and new center development.
On March 30, 1998, the Company entered into a definitive agreement to sell
certain non-core assets, specifically the Company's mobile subsidiary Medical
Diagnostics, Inc. ("MDI") to Alliance Imaging Inc. for $35.6 million in cash
less debt to be assumed of approximately $6.5 million. The transaction
agreement, which is subject to Hart-Scott-Rodino clearance, is expected to close
in May 1998. The proceeds of the sale will be used to reduce the Company's debt
and to bolster the Company's cash reserves. Mobile imaging operations do not
conform with the Company's core business of fixed site MRI and mutimodality
imaging centers.
In the year ended December 31, 1997, the Company recorded a non-cash
impairment charge of $92.9 million. The majority of acquired businesses and
imaging centers which comprise the Company were purchased in 1996. Therefore
1997 was the first year of uninterrupted operation for such acquired entities as
a part of the Company's consolidated group. During 1997, current management
became aware that many of the acquired centers were not performing as originally
projected. At year-end all acquired businesses were analyzed in depth, in light
of the additional operating data during the period of the Company's ownership,
to determine whether such shortfalls in performance were of a temporary nature
and if current and expected future operating income would be sufficient to cover
annual amortization of intangible and long-lived assets acquired. Management has
recorded impairment losses for the difference between the fair value and
carrying value of those centers for which the sum of the expected cash flows
does not cover the carrying value of the assets acquired. Management is
currently investigating the causes of such performance shortfalls including, in
some cases, to what extent the impairment losses are a result of
misrepresentations by sellers. For additional information see Notes 2, 4, 5 and
23 to Consolidated Financial Statements.
19
<PAGE>
The following table sets forth items of income and expense as a percentage of
total revenues:
<TABLE>
<CAPTION>
YEARS ENDED DECEMBER 31,
------------------------
1997 1996 1995
------ ------ ------
<S> <C> <C> <C>
REVENUE
Net patient revenue 88.3 % 88.8 % 100.0 %
Other revenue 11.7 11.2 0.0
TOTAL REVENUE 100.0 100.0 100.0
----- ----- -----
OPERATING EXPENSES
General and administrative 76.6 70.7 66.2
Asset impairment losses 42.9 .4 --
Bad debt expense 8.2 3.9 2.0
Depreciation 8.9 6.5 7.4
Amortization 5.0 4.6 2.8
Loss on settlement of lawsuits 2.6 2.1 --
Settlement with Former Chief Executive Officer .8 -- --
Stock based compensation .6 2.1 .7
Compensation to terminated consultant -- 5.5 .5
Loss on sale of stock of subsidiaries, net -- 3.0 --
----- ----- -----
TOTAL OPERATING EXPENSES 145.6 98.8 79.6
----- ----- -----
INCOME (LOSS) FROM OPERATIONS (45.6) 1.2 20.4
OTHER INCOME (EXPENSE)
Interest expense (8.8) (8.8) (4.3)
Interest and other income (expense) .5 2.3 (1.0)
Gain on marketable equity securities .2 -- --
Non-cash finance charge -- -- (1.4)
----- ----- -----
TOTAL OTHER INCOME (EXPENSE) (8.1) (6.5) (6.7)
----- ----- -----
Income (loss) before minority interest, provision (benefit)
for income taxes and extraordinary item (53.7) (5.3) 13.7
Minority interest in income of subsidiaries 1.1 1.5 1.0
Provision (benefit) for income taxes (.8) (.6) 2.5
----- ----- -----
INCOME (LOSS) BEFORE EXTRAORDINARY ITEM (54.0) ( 6.2) 10.3
----- ----- -----
Extraordinary item, net of taxes -- -- 1.0
----- ------ -----
NET INCOME (LOSS) (54.0) % ( 6.2) % 11.3 %
===== ===== =====
</TABLE>
20
<PAGE>
YEAR ENDED DECEMBER 31, 1997 COMPARED WITH YEAR ENDED DECEMBER 31, 1996
Revenue for 1997 increased over 1996 revenues by approximately 212 percent
reflecting increased scan volumes resulting primarily from the Company's growth
through acquisitions. Despite this increase in revenues, for the year ended
December 31, 1997, the Company incurred a net loss of $116.7 million as compared
to a net loss for the prior year of $6.3 million.
The loss for 1997 is primarily attributable to a $92.9 million charge
related to impairment losses more fully discussed above in "Recent
Developments". The 1997 loss also reflects approximately $17.6 million of bad
debt expense, which increased as a percentage of revenues to approximately 8.2
percent in 1997 from 3.9 percent in 1996. This increase in bad debt expense is
attributable both to the Company's overall growth, and to an increase in
accounts receivable resulting from a failure to fully collect receivables on the
older billing and collection systems during the phase-in of a new billing and
collection system. The new system was affected adversely by training and
operational related problems as well as by the installation complexity. In
addition, collections were negatively affected by inefficiencies in realizing
receivables in respect to patient co-payments and deductibles. Despite the
devotion by the Company of providing additional resources to resolve these
problems, there can be no assurance that the Company's efforts will result in a
satisfactory level of collections or permit a future reduction in bad debt
expense. See "Liquidity and Capital Resources" below.
General and administrative expenses for 1997 increased $93.4 million
from $72.2 million in 1996 to $165.6 in 1997 and increased as a percentage of
revenue from 70.7% in 1996 to 76.6% in 1997. The percentage increase equates to
approximately $12.8 million and is primarily the result of increased legal and
professional fees associated with the various legal and regulatory matters
discussed more fully in Notes 10, 19 and 20 of Notes to Consolidated Financial
Statements. In addition, the Company separately recorded a $5.7 million loss in
connection with the settlement of litigation. See Note 20 of Notes to
Consolidated Financial Statements.
Depreciation and amortization expense as a percentage of revenues
increased to 13.9 percent from 11.1 percent. This increase is attributable to
higher levels of property and equipment and goodwill associated with the
acquisition of Medical Diagnostics, Inc. ("MDI").
Interest expense also increased significantly as a result of the
Company's higher borrowings incurred to support its growth, capital expenditures
related to the construction and expansion of existing Facilities, as well as the
replacement and enhancement of equipment, and the deficit in operating cash
flow.
YEAR ENDED DECEMBER 31, 1996 COMPARED WITH YEAR ENDED DECEMBER 31, 1995
Net revenues increased $72.6 million from $29.4 million in 1995 to $102.1
million in 1996. The net revenue increase reflects (i) primarily the acquisition
of Facilities which accounted for approximately $70 million of the increase, and
(ii) enhanced marketing efforts by the Company.
General and administrative expenses for 1996 increased $52.7 million from
$19.5 million in 1995 to $72.2 million in 1996, and increased as a percentage of
net revenues from 66.2% to 70.7%. The increase in expense relates to (i) the
acquisition of imaging centers, (ii) the increase in corporate overhead as the
Company consolidated or commenced consolidation of most administrative
operations at its headquarters and regional operating offices and (iii) legal,
accounting and other general expenses. Bad debt expense also increased $3.4
million from $577,000 in 1995 to $4.0 million in 1996. This was related to the
increase in net revenues discussed above and specified write-offs of certain
accounts receivable.
21
<PAGE>
Amortization expense resulting from the goodwill and other intangibles
arising from acquisitions increased $3.8 million from $834,000 in 1995 to $4.6
million in 1996.
Depreciation expense increased $4.4 million from $2.2 million in 1995 to
$6.6 million in 1996, primarily due to the acquisitions during the year and a
full year's depreciation of 1995 acquisitions.
Interest expense increased $7.7 million from $1.3 million in 1995 to $9.0
million in 1996. This resulted primarily from the convertible debenture
financing of $57.5 million at 9% interest which was consummated in March 1996,
and also as a result of equipment and other debt associated with acquisitions.
Included in interest and other income is interest income of $2.3 million in
1996, an increase of $2.1 million over 1995. Such increase was due to the
proceeds raised from the debentures as well as from conversion of warrants
during 1996 which increased cash balances for portions of the year 1996.
In addition, during 1996 the Company recognized $5.6 million of
compensation expense related to Coyote Consulting (see Note 12 of Notes to
Consolidated Financial Statements). Further, the Company recognized $2.1 million
of expenses in relation to losses on settlements of claims (see Note 10 of Notes
to Consolidated Financial Statements), and Stock-based compensation increased
$2.0 million from $213,000 in 1995 to $2.2 million in 1996 as a result of
issuance of Common Stock to employees and directors, as well as non-employees.
The Company also incurred a net loss on the sale of its clinical blood labs of
$3.4 million.
For the year ended December 31, 1996 a net loss of $6.3 million was
generated. This was significantly impacted by certain non-recurring or unusual
expenses such as: (i) $5.6 million of compensation expense related to Coyote
Consulting; (ii) $2.1 million of expenses related to losses on settlements of
claims; (iii) $3.4 million of a net loss on the sale of the Company's clinical
blood labs; and (iv) $3.2 million of unusual accruals associated with legal and
accounting fees.
Liquidity and Capital Resources
For information regarding the Company's credit facilities and certain
contingencies related thereto, see Note 6 of Notes to Consolidated Financial
Statements.
At December 31, 1997, the Company had working capital of $14.6 million,
compared to $6.4 million at December 31, 1996. The increase was primarily due to
borrowings under the Company's credit facilities. The Company's primary short
term liquidity requirements include the current portion of long term debt and
capital leases, other current liabilities, including $5.3 million payable in
connection with the settlement of certain shareholder litigation described more
fully in Note 20 of Notes to Consolidated Financial Statements, and capital
expenditures related to the opening of new Facilities, the replacement and
enhancement of existing imaging equipment and improvements in the Company's
management information systems. The Company had approximately $17.5 million in
cash at year end 1997. Long term liquidity requirements at December 31, 1997
include $186.8 million in long term debt and capitalized leases of which $64.5
million is due during 1999, $22.8 million is due during 2000 and the balance is
due thereafter.
Net cash used in operating activities was $7.8 million during 1997
compared to $6.7 million in cash provided by operating activities during 1996,
primarily resulting from growth in accounts receivable and the legal, accounting
and other professional fees described above.
Net cash used in investing activities was $37.6 million for 1997 compared
to $122.0 million in 1996. Cash used in investing activities primarily relates
to acquisitions and equipment purchases.
22
<PAGE>
Net cash from financing activities was $44.3 million during 1997 compared
to $129.5 million in 1996. This included proceeds from borrowings totaling $78.7
million, the exercise of stock options totaling $106,000 and the repayment of
capital lease and debt obligations totaling $34.6 million.
During 1997, but for borrowings under the facilities described in Notes 6
and 8 of Notes to Consolidated Financial Statements, the Company's cash position
deteriorated as a result of higher legal and accounting fees related to
regulatory matters and litigation described in "Business - Legal Proceedings,
Market for Registrant's Common Equity and Related Stockholder Matters," and
Notes 10 and 20 of Notes to Consolidated Financial Statements, the repayment of
$34.6 million in debt incurred to acquire Facilities and the payment of $18.9
million in capital expenditures to upgrade and replace imaging equipment and
management information system enhancements. In addition, cash balances were
negatively affected by an increase in bad debt expense and accounts receivable
resulting from a failure to fully collect receivables from third party payors,
in part as a function of the Company's conversion to a new centralized billing
and collection system and in part, as a function of inefficiencies in realizing
on the collection of patient copayments and deductible payments. This reduction
in cash balances has continued during the first quarter of 1998 and in response,
the Company has devoted additional resources to the collection of accounts
receivable and implemented intense remedial efforts with respect thereto. The
Company has also identified the strategy described above, including the sale of
MDI, as well as the potential sale of other non-core assets. See "Overview and
"Recent Developments". If the Company's strategy is not sufficient or if
collections cannot be improved to the extent necessary, the Company's liquidity
and financial condition could be materially and adversely affected. In addition,
if the uncertainties with respect to the Company's credit facilities described
in Note 6 of Notes to Consolidated Financial Statements cannot be satisfactorily
resolved, the Company may be required to pay down or refinance all or a portion
of such credit facilities. In any such event the Company would likely need to
seek new financing, either through an equity offering, additional borrowings or
asset sales. There can be no assurance that the Company would be able to obtain
such new financing or effect such asset sales in a timely fashion or upon
acceptable terms, or if at all.
For additional information regarding contingencies and uncertainties
related to litigation and regulatory matters, see Item 3 - Legal Proceedings,
Item 4 - Market for Registrant's Common Equity and Related Stockholder Matters
and Note 20 of Notes to Consolidated Financial Statements.
COMPUTER TECHNOLOGIES AND YEAR 2000 COMPLIANCE
The Company is aware of the issues associated with the programming code in
existing computer systems as the year 2000 approaches. Many existing computer
programs use only two digits to identify a year in the date field. The issue is
whether such code exists in the Company's mission-critical applications and if
that code will produce accurate information with relation to date-sensitive
calculations after the turn of the century.
The Company has completed a thorough review of its material computer
applications. In 1996, the Company began installing a new $9.5 million
state-of-the-art billing and collection system as well as a new accounting
system. These new systems are Year 2000 compliant. There are many facility
systems acquired by the Company as a result of its acquisitions which may not be
Year 2000 compliant. However, the Company anticipates that all such systems will
be replaced by its new systems before the year 2000. The Company has received
written confirmation from its vendors that its new systems are currently Year
2000 compliant or will be made Year 2000 compliant before year 2000. The cost to
be incurred by the Company relating to the year 2000 compliance for these
systems is currently not expected to be material.
The Company has initiated a program to determine whether the computer
applications of its significant payors and suppliers will be upgraded in a
timely manner. The Company has also initiated a program to determine whether
embedded applications which control certain medical and other equipment will be
affected. The Company has not yet completed these reviews. The nature of the
Company's business is such that any failure to these types of applications may
have a material adverse effect on its business.
Because of the many uncertainties associated with Year 2000 compliance
issues, and because the
23
<PAGE>
Company's assessment is necessarily based on information from third
party-vendors, payors and suppliers, there can be no assurance that the
Company's assessment is correct or as to the materiality or effect of any
failure of such assessment to be correct.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
The response to this item is included in a separate section of this
Report. See Index to Consolidated Financial Statements on Page 29 of this Form
10-K.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE.
Effective June 13, 1996 the Company changed its independent accountants
from Moore Stephens, P.C. formerly known as Mortenson and Associates, P.C.
("Mortenson") to Arthur Andersen LLP because of its desire to have a "Big Six"
accounting firm as its auditor. The Mortenson's report on the Company's
financial statements for the two years ended December 31, 1995 did not contain
an adverse opinion or disclaimer of opinion and was not qualified as to
uncertainty, audit scope or accounting principles. The decision to change
accountants was recommended and approved by the Board of Directors of the
Company. Since January 1, 1994, there were no disagreements with Mortenson on
any matter of accounting principles or practices, financial statement disclosure
or auditing scope or procedure. No reportable events as defined under Rule
304(a)(1)(v) of Regulation S-K occurred since January 1, 1994. In addition, no
reportable events as defined under 304(a)(2) of Regulation S-K occurred since
January 1, 1994.
PART III
The information required in Part III of this Form 10-K will be filed with
the SEC pursuant to General Instruction G (3) to Form 10-K in an amendment to
this Form 10-K.
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K.
(a) Documents Filed as Part of this Report
(1) Financial Statements
See "Item 8. Financial Statements and Supplementary Data" for
Financial Statements included in this Annual Report on Form 10-K.
(2) Schedule II, Valuation and Qualifying Accounts and Reserves, for
each of the three years ended December 31, 1997 is submitted
herewith.
(3) Exhibits -- (See Index to Exhibits included elsewhere herein.)
(b) Reports on Form 8-K
No reports on Form 8-K were filed during the quarter ended December 31,
1997
24
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
US DIAGNOSTIC INC.
Date: April 14, 1998 By: /s/ JOSEPH A. PAUL
------------------
Joseph A. Paul
Chief Executive Officer, President,
and Director
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons in the capacities and on
the dates indicated.
<TABLE>
<CAPTION>
NAME TITLE DATE
- ---- ----- ----
<S> <C> <C>
/s/ L.E. RICHEY, MD Co-Chairman of the Board and Director April 14, 1998
- --------------------------
L.E Richey, MD
/s/ C. KEITH HARTLEY Co-Chairman of the Board and Director April 14, 1998
- --------------------------
C. Keith Hartley
/s/ JOSEPH A. PAUL Chief Executive Officer, President April 14, 1998
- -------------------------- and Director (Principal Executive Officer)
Joseph A. Paul
/s/ J. WAYNE MOOR Executive Vice President, Chief Financial April 14, 1998
- -------------------------- Officer and Assistant Secretary (Principal
J. Wayne Moor Financial Officer and Principal Accounting
Officer)
/s/ GORDON RAUSSER Director April 14, 1998
- --------------------------
Gordon Rausser
/s/ MICHAEL O'HANLON Director April 14, 1998
- ---------------------------
Michael O'Hanlon
</TABLE>
25
<PAGE>
EXHIBIT INDEX
2.1 Agreement and Plan of Merger, dated as of August 1,1996, among the
Company, MICA Acquiring Corporation, a California corporation and
Medical Imaging Centers of America., a California Corporation.(11)
3.1 Certificate of Incorporation of the Registrant.(1)
3.2 Bylaws of the Registrant.(2)
4.1 Form of Unit Purchase Option.(1)
4.2 Form of Warrant Agreement.(1)
4.3 Escrow Agreement.(1)
4.4 Indenture relating to 9% Subordinated Convertible Debentures by the
Company to American Stock Transfer & Trust Company, as Trustee, dated
as of March 29, 1996.(14)
4.5 Registration Rights Agreement.(14)
4.6 Form of Amended and Restated 6 1/2% Convertible Negotiable Note Due
June 30, 2001. (17)
4.7 First Supplemental Indenture to Indenture relating to 9% Subordinated
Convertible Debentures dated as of March 24, 1998.
10.1 1993 Stock Option Plan.(1)
10.2 Asset Purchase Agreement among the Company, Columbus Diagnostic Center
Inc. and Physicians Diagnostic Associates of Columbus, L.P.(1)
10.3 Employment Agreement with Robert Burke, M.D.(1)
10.4 Equipment Lease with Ventura Partners.(1)
10.5 Lease between the Company and United Properties Co.(1)
10.6 Asset Purchase Agreement dated as of December 31, 1994 among the
Company, Santa Fe Imaging Center, Ltd. and Santa Fe Imaging Center
Inc., a subsidiary of the Company.(2)
10.7 Equipment Lease dated as of December 31, 1994 between Santa Fe Imaging
Center, Ltd. and Santa Fe Imaging Center Inc., a subsidiary of the
Company.(2)
10.8 Property Lease dated as of December 31, 1994 among Santa Fe Imaging
Center, Ltd. and Santa Fe Imaging Center Inc., a subsidiary of the
Company.(2)
10.9 Asset Purchase Agreement dated as of February 27, 1995 among the
Company, Open Air MRI, Inc., Community Radiology of Virginia, Inc. and
CROV Acquisition Corp., a subsidiary of the Company.(3)
10.10 Radiology Agreement dated as of February 27, 1995 between Stephen
Raskin, M.D., P.C. and CROV Acquisition Corp., a subsidiary of the
Company.(3)
10.11 Management Agreement dated as of February 27, 1995 among the Company,
Open Air MRI, Inc., Community Radiology of Virginia, Inc. and CROV
Acquisition Corp., a subsidiary of the Company.(3)
10.12 Escrow Agreement dated as of February 27, 1995 among the Company, Open
Air MRI, Inc., Community Radiology of Virginia, Inc. and CROV
Acquisition Corp., a subsidiary of the Company.(3)
10.13 Guaranty dated as of February 27, 1995.(3)
10.14 Stock Purchase Agreement dated as of February 15, 1995 among the
Company, Laborde Diagnostics, Inc. and Jeffrey J. Laborde, M.D.(4)
10.15 Employment Agreement dated as of February 15, 1995 among the Company,
Laborde Diagnostics, Inc. and Jeffrey J. Laborde, M.D.(4)
10.16 1995 Long Term Incentive Plan.(5)
10.17 Consulting Agreement with Gordon Rausser.(5)
10.18 Consulting Agreement with Coyote Consulting.(5)
10.19 Consulting Agreement with Sawgrass Consulting.(5)
10.20 Asset Purchase Agreement dated as of October 10, 1995 among the
Company, Central Alabama Medical Enterprises, Inc. and Advanced Medical
Imaging Center, Inc., a subsidiary of the Company.(6)
10.21 Property Lease dated as of October 10, 1995 among the Company, Central
Alabama Medical Enterprises, Inc. and Advanced Medical Imaging Center,
Inc., a subsidiary of the Company.(6)
10.22 Employment Agreement dated as of August 1, 1995 between the Company and
David Cohen.(6)
26
<PAGE>
10.23 Amendment to Employment Agreement of Jeffrey Goffman.(7)
10.24 Amendment to Coyote Consulting Agreement.(7)
10.25 Merger Agreement dated as of February 27, 1996 among the Company, U.S.
Imaging, Inc. and U.S.I. Acquisition Inc., a subsidiary of the
Company.(8)
10.26 Escrow Agreement dated as of June 4, 1996 among the Company and the
Reese General Trust.(8)
10.27 Asset Purchase Agreement dated as of June 28, 1996 among the Company,
Allegheny Open MRI/CT Group and USDL Pittsburgh Inc., a subsidiary of
the Company.(9)
10.28 Registration and Sale Rights Agreement dated as of June 28, 1996 among
the Company and the Allegheny Open MRI/CT Group.(9)
10.29 Employment Agreement dated as of June 18, 1996 between the Company and
Joseph Paul.(9)
10.30 Employment Agreement dated as of June 1, 1996 between the Company and
Michael Karsch.(9)
10.31 Employment Agreement dated as of July 1, 1996 between the Company and
Andrew Shaw. (9)
10.32 Stock Purchase Agreement dated as of June 20, 1996 among the Company,
MediTek Health Corporation and HEICO Corporation.(10)
10.33 Registration and Sale Rights Agreement dated as of June 20, 1996
between the Company and HEICO Corporation.(10)
10.34 Termination Agreement dated January 29, 1997 among the Company, Coyote
Consulting & Financial Services LLC and Keith Greenberg.(12)
10.35 Loan and Security Agreement and Secured Promissory Note among US
Diagnostic Inc. and DVI Credit Corporation dated as of February 25,
1997.(15)
10.36 Subscription Agreement between Diversified Therapy Corp. and US
Diagnostic Inc.(15)
10.37 Employment Agreement dated August 31, 1994 between US Diagnostic Labs,
Inc. and Jeffrey A. Goffman.(15)
10.38 Amended and restated Employment Agreement dated August 9, 1996 between
the Company and Todd R. Smith.(15)
10.39 Employment Agreement dated June 30, 1995 between the Company and Amos
F. Almand, III.(15)
10.40 Employment Agreement dated October 15, 1996 between the Company and Len
Platt.(15)
10.41 Employment Agreement dated May 1, 1996 between the Company and Alan M.
Winakor.(15)
10.42 Employment Agreement dated October 15, 1996 between the Company and
Arthur Quillo.(15)
10.43 Consulting Agreement dated October 1, 1996 between the Company and
Robert Burke, M.D.(15)
10.44 Memorandum of Understanding.(16) 10.45 Settlement Agreement and General
Release dated July 11,1997 between the Company and Jeffrey Goffman.
(17)
10.46 Escrow Agreement between the Company, Jeffrey Goffman and Roberto
Martinez. (17)
10.47 Promissory Note between the Company and Jeffrey Goffman. (17)
10.48 Voting Agreement between the Company and Jeffrey Goffman. (17)
10.49 Employment Agreement dated June 18, 1997 between the Company and Wayne
Moor. (17)
10.50 Employment Agreement dated October 20, 1997 between the Company and
Leon Maraist. (18)
10.51 Settlement Agreement and General Release dated September 30, 1997
between the Company and Jeffrey Goffman. (18)
10.52 Form of Loan and Security Agreement among Medical Diagnostics Inc., the
Company and DVI Financial Services Inc. dated September 29, 1997. (18)
10.53 Form of Secured Promissory Note due October 1, 2002 by Medical
Diagnostics Inc. to DVI Financial Services Inc. (18)
10.54 Unconditional Continuing Guaranty dated September 29, 1997 for the
benefit of DVI Financial Services Inc. by the Company.(18)
10.55 Stock Pledge Agreement dated September 29, 1997 between the Company DVI
Financial Services Inc. and DVI Business Credit Corporation. (18)
10.56 Common Stock Purchase Warrant dated September 29, 1997 of the Company
issued to DVI Financial Services Inc. (18)
10.57 Common Stock Purchase Warrant dated September 29, 1997 of the Company
issued to DVI Financial Services Inc. (18)
10.58 Letter of Agreement dated September 29, 1997 between the Company and
DVI Business Credit Corporation confirming amendment of Loan and
Security Agreement dated as of February 25, 1997. (18)
27
<PAGE>
16.1 Letter re change in certifying accountant from Mortenson and
Associates, P.C.(8)
21 Subsidiaries.
23.1 Consent of Authur Andersen LLP
23.2 Consent of Moore Stephens, P.C.
27 Financial Data Schedule.
99.1 Press release dated January 29, 1997.(12)
99.2 Complaints filed in the United States District Court of the Southern
District of Florida entitled Lynne M. Golden, Trustee, UAD 1/6/96;
Lynne M. Golden Trust; individually and on behalf of a class of all
persons similarly situated vs. U.S. Diagnostic Inc., Jeffrey A.
Goffman, Keith G. Greenberg, Joseph A. Paul, Robert D. Burke; Amos F.
Almand, III and Coyote Consulting & Financial Services LLC: Muriel
Edelstein vs. U.S. Diagnostic Inc., Jeffrey A. Goffman, Joseph A. Paul,
Dr. Robert D. Burke and Keith G. Greenberg: Steven Shapiro, Plaintiff;
vs. U.S. Diagnostic Inc., et al, Defendants: Sandra Neuman, Plaintiff
vs. U.S. Diagnostic Inc., et al., Defendants.(12)
99.3 Permanent Injunction against Keith Greenberg.(12)
99.4 Information and Guilty Plea by Keith Greenberg.(12)
99.5 Press Release of U.S. Diagnostic Inc. dated February 3, 1997.(13)
99.6 Press Release of U.S. Diagnostic Inc. dated July 31, 1997.(16)
- -----------------------------------
(1) Incorporated by reference to the Company's Registration Statement on
Form SB-2 (file no. 33- 73414).
(2) Incorporated by reference to the Company's Report on Form 8-K dated
January 11, 1995.
(3) Incorporated by reference to the Company's Report on Form 8-K dated
February 27, 1995.
(4) Incorporated by reference to the Company's Report on Form 8-K dated
March 20,1994.
(5) Incorporated by reference to the Company's Registration Statement on
Form SB-2 (file no. 33- 93536).
(6) Incorporated by reference to the Company's Report on Form 8-K dated
October 30,1995.
(7) Incorporated by reference to the Company's Annual Report on Form 10-KSB
for the year ended December 31,1995.
(8) Incorporated by reference to the Company's Report on Form 8-K dated
June 5, 1996.
(9) Incorporated by reference to the Company's Report on Form 8-K dated
June 28, 1996.
(10) Incorporated by reference to the Company's Report on Form 8-K dated
July 24, 1996.
(11) Incorporated by reference to the Company's Report on Form 10-QSB for
the three months ended June 30, 1996.
(12) Incorporated by reference to the Company's Report on Form 8-K dated
January 29, 1997.
(13) Incorporated by reference to the Company's Report on Form 8-K dated
February 3, 1997.
(14) Incorporated by reference to the Company's Registration Statement on
Form S-3 dated June 6, 1996.
(15) Incorporated by reference to the Company's Annual Report on Form
10-KSB/A for the year ended December 31, 1996.
(16) Incorporated by reference to the Company's Report on Form 8-K dated
July 31, 1997.
(17) Incorporated by reference to the Company's Form 10-Q for the quarterly
period ended June 30, 1997.
(18) Incorporated by reference to the Company's Form 10-Q for the quarterly
period ended September 30, 1997.
28
<PAGE>
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
HISTORICAL CONSOLIDATED FINANCIAL STATEMENTS
<TABLE>
<CAPTION>
<S> <C>
Report of Independent Certified Public Accountants (1997 and 1996).......................... F-1
Independent Auditor's Report (1995).......................................................... F-2
Consolidated Balance Sheets as of December 31, 1997 and 1996................................. F-3
Consolidated Statements of Operations for each of the three years ended
December 31, 1997......................................................................... F-5
Consolidated Statements of Cash Flows for each of the three years ended
December 31, 1997........................................................................... F-6
Consolidated Statements of Stockholders' Equity for each of the three years
ended December 31, 1997................................................................... F-8
Notes to Consolidated Financial Statements................................................... F-9
</TABLE>
29
<PAGE>
REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
To the Stockholders and Board of Directors of
US Diagnostic Inc.:
We have audited the accompanying consolidated balance sheets of US
Diagnostic Inc. (a Delaware corporation) and its subsidiaries as of December 31,
1997 and 1996, and the related consolidated statements of operations,
stockholders' equity and cash flows for each of the two years in the period
ended December 31, 1997. These financial statements are the responsibility of
the Company's management. Our responsibility is to express an opinion on these
financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present
fairly, in all material respects, the financial position of US Diagnostic Inc.
and subsidiaries as of December 31, 1997 and 1996, and the results of their
operations and their cash flows for each of the two years in the period ended
December 31, 1997 in conformity with generally accepted accounting principles.
Our audits were made for the purpose of forming an opinion on the basic
financial statements taken as a whole. Schedule II for each of the two years in
the period ended December 31, 1997 is presented for purposes of complying with
the Securities and Exchange Commission's rules and is not a required part of the
basic financial statements. This schedule has been subjected to the auditing
procedures applied in our audits of the basic financial statements and, in our
opinion, fairly states, in all material respects, the financial data required to
be set forth therein in relation to the basic financial statements taken as a
whole.
Arthur Andersen LLP
West Palm Beach, Florida,
April 13, 1998.
F-1
<PAGE>
INDEPENDENT AUDITOR'S REPORT
To the Stockholders and Board of Directors of
US Diagnostic Inc.
We have audited the accompanying consolidated statement of operations,
stockholders' equity, and cash flows of US Diagnostic Inc. [formerly U.S.
Diagnostic Labs Inc.] and its subsidiaries for the year ended December 31, 1995.
These consolidated financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these consolidated
financial statements based on our audit.
We conducted our audit in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are
free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the consolidated financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
consolidated financial statement presentation. We believe that our audit
provides a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above
present fairly, in all material respects, the consolidated results of operations
and cash flows of US Diagnostic Inc. [formerly U.S. Diagnostic Labs Inc.] and
its subsidiaries for the year ended December 31, 1995, in conformity with
generally accepted accounting principles.
Our audit was made for the purpose of forming an opinion on the basic
financial statements taken as a whole. Schedule II for the year ended December
31, 1995 is presented for purposes of complying with the Securities and Exchange
Commission's rules and is not part of the basic financial statements. This
schedule has been subjected to the auditing procedures applied in the audit of
the basic financial statements and, in our opinion, fairly states, in all
material respects, the financial data required to be set forth therein in
relation to the basic financial statements taken as a whole.
MOORE STEPHENS, P.C.
Certified Public Accountants
Cranford, New Jersey,
February 20, 1996.
(Except for Note 22 as to which the date is May 10, 1996)
F-2
<PAGE>
<TABLE>
<CAPTION>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 1997 AND 1996
- --------------------------------------------------------------------------------
In thousands, except share data
ASSETS 1997 1996
--------- ---------
<S> <C> <C>
CURRENT ASSETS
Cash and cash equivalents $ 17,460 $ 18,641
Accounts receivable, net of allowance for bad debts of $17,312
and $9,670 in 1997 and 1996, respectively 52,270 38,266
Other receivables, net of allowance for bad debts of $0
and $923 in 1997 and 1996, respectively 6,467 9,615
Investment in marketable equity securities ($6,425 at cost) -- 7,280
Prepaid expenses and other current assets 7,731 6,003
--------- ---------
TOTAL CURRENT ASSETS 83,928 79,805
--------- ---------
PROPERTY AND EQUIPMENT, net of accumulated depreciation and amortization
of $25,330 and $11,825 in 1997 and 1996, respectively 91,567 79,946
INTANGIBLE ASSETS, net of accumulated amortization of $13,890
and $4,899 in 1997 and 1996, respectively 103,898 163,675
OTHER ASSETS 4,277 5,398
INVESTMENT IN AND ADVANCES TO UNCONSOLIDATED SUBSIDIARIES 4,329 10,199
--------- ---------
TOTAL ASSETS $ 287,999 $ 339,023
========= =========
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable and accrued expenses $ 26,418 $ 21,054
Shareholder class action settlement payable 5,288 --
Current portion of long-term debt 18,590 27,336
Obligations under capital leases - current portion 9,155 10,291
Other current liabilities 7,350 6,358
Purchase price due on companies acquired 2,485 8,338
--------- ---------
TOTAL CURRENT LIABILITIES 69,286 73,377
--------- ---------
Subordinated convertible debentures 56,246 56,007
Long-term debt, net of current portion 118,999 42,359
Obligations under capital leases, net of current portion 11,573 18,704
Other liabilities 4,729 6,914
--------- ---------
TOTAL LIABILITIES 260,833 197,361
--------- ---------
MINORITY INTEREST 1,826 8,150
COMMITMENTS AND CONTINGENCIES (Notes 14 and 20) -- --
STOCKHOLDERS' EQUITY
Preferred stock, $.01 par value; 5,000,000 shares authorized; none issued -- --
Common stock, $.01 par value; 50,000,000 shares authorized; 22,889,633 and
23,749,217 shares issued and outstanding in 1997 and 1996, respectively 229 237
Additional paid-in capital 147,850 141,941
Unrealized gain on marketable equity securities, net of tax -- 526
Deferred stock-based compensation (2,192) (5,357)
Accumulated deficit (120,547) (3,835)
--------- ---------
TOTAL STOCKHOLDERS' EQUITY 25,340 133,512
--------- ---------
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY $ 287,999 $ 339,023
========= =========
</TABLE>
The accompanying notes to consolidated financial statements are an integral part
of these statements.
F-3
<PAGE>
<TABLE>
<CAPTION>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
CONSOLIDATED STATEMENTS OF OPERATIONS
- --------------------------------------------------------------------------------
In thousands, except per share data
YEARS ENDED DECEMBER 31,
-----------------------------------
1997 1996 1995
--------- --------- ---------
<S> <C> <C> <C>
REVENUE
Net patient revenue $ 190,839 $ 90,587 $ 29,416
Other revenue 25,383 11,474 --
--------- --------- ---------
TOTAL REVENUE 216,222 102,061 29,416
--------- --------- ---------
OPERATING EXPENSES
General and administrative 165,549 72,200 19,485
Asset impairment losses 92,853 390 --
Bad debt expense 17,630 4,016 577
Depreciation 19,232 6,595 2,170
Amortization 10,790 4,649 834
Loss on settlement of lawsuits 5,739 2,125 --
Settlement with Former Chief Executive Officer 1,809 -- --
Stock-based compensation 1,261 2,168 213
Compensation to terminated consultant -- 5,597 138
Loss on sale of stock of subsidiaries, net -- 3,077 --
--------- --------- ---------
TOTAL OPERATING EXPENSES 314,863 100,817 23,417
--------- --------- ---------
INCOME (LOSS) FROM OPERATIONS (98,641) 1,244 5,999
OTHER INCOME (EXPENSE)
Interest expense (19,114) (8,974) (1,276)
Interest and other income (expense) 1,225 2,375 (275)
Gain on marketable equity securities 407 -- --
Non-cash finance charge -- -- (414)
--------- --------- ---------
TOTAL OTHER INCOME (EXPENSE) (17,482) (6,599) (1,965)
--------- --------- ---------
Income (loss) before minority interest, provision (benefit)
for income taxes and extraordinary item (116,123) (5,355) 4,034
Minority interest in income of subsidiaries 2,428 1,576 280
Provision (benefit) for income taxes (1,839) (600) 729
--------- --------- ---------
INCOME (LOSS) BEFORE EXTRAORDINARY ITEM (116,712) (6,331) 3,025
--------- --------- ---------
Extraordinary item, net of taxes -- -- 306
--------- --------- ---------
NET INCOME (LOSS) $(116,712) $ (6,331) $ 3,331
========= ========= =========
BASIC EARNINGS PER COMMON SHARE
Income (loss) before extraordinary item $ (5.26) $ (.48) $ .70
Extraordinary item -- .07
--------- --------- ---------
Net income (loss) $ (5.26) $ (.48) $ .77
========= ========= =========
Average common shares outstanding 22,182 13,272 4,304
========= ========= =========
DILUTED EARNINGS PER COMMON SHARE
Income (loss) before extraordinary item $ (5.26) $ (.48) $ .64
Extraordinary item -- -- .06
--------- --------- ---------
Net income (loss) $ (5.26) $ (.48) $ .70
========= ========= =========
Average common and dilutive equivalent shares
outstanding 22,182 13,272 4,771
========= ========= =========
</TABLE>
The accompanying notes to consolidated financial statements are an integral part
of these statements.
F-4
<PAGE>
<TABLE>
<CAPTION>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
- --------------------------------------------------------------------------------
In thousands
RETAINED TOTAL
COMMON COMMON PAID-IN UNREALIZED DEFERRED EARNINGS STOCKHOLDERS'
SHARES STOCK CAPITAL GAIN COMPENSATION (DEFICIT) EQUITY
------ ------ -------- ---------- ------------ --------- -------------
<S> <C> <C> <C> <C> <C> <C> <C>
BALANCE - JANUARY 1, 1995 4,079 $ 41 $ 9,431 $-- $ (599) $ (835) $ 8,038
Warrants exercised 235 2 802 -- -- -- 804
Common stock issued for
acquisitions 684 7 2,981 -- -- -- 2,988
Restricted stock issued 150 1 524 -- (525) -- --
Common stock issued to
unrelated individuals 28 -- 138 -- (138) -- --
Common stock issued -
secondary offering 1,857 19 9,078 -- -- -- 9,097
Amortization of deferred
compensation -- -- -- -- 235 -- 235
Net income -- -- -- -- -- 3,331 3,331
------ ---- -------- ---- ------- ------- ---------
BALANCE - DECEMBER 31, 1995 7,033 70 22,954 -- (1,027) 2,496 24,493
------ ---- -------- ---- ------- ------- ---------
Common stock and options
issued for acquisitions 3,046 30 15,346 -- -- -- 15,376
Stock options exercised 211 2 1,074 -- -- -- 1,076
Compensation cost - stock
options granted -- -- 2,780 -- (2,559) -- 221
Warrants exercised 13,129 131 90,362 -- -- -- 90,493
Common stock issued in
settlement of litigation 88 1 778 -- -- -- 779
Restricted stock issued -- -- 4,867 -- (4,867) -- --
Common stock issued to
cancel consulting agreement 93 1 580 -- -- -- 581
Common stock issued for
debt conversion 149 2 761 -- -- -- 763
Fair value of detachable warrants -
convertible debentures -- -- 1,672 -- -- -- 1,672
Income tax benefit from options
exercised -- -- 767 -- -- -- 767
Unrealized gain - marketable
equity securities -- -- -- 526 -- -- 526
Amortization of deferred compensation -- -- -- -- 3,096 -- 3,096
Net loss -- -- -- -- -- (6,331) (6,331)
------ ---- -------- ---- ------- ------- ---------
BALANCE -DECEMBER 31, 1996 23,749 $237 $141,941 $526 $(5,357) $(3,835) $ 133,512
------ ---- -------- ---- ------- ------- ---------
The accompanying notes to consolidated financial statements are an integral part
of these statements.
F-5
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (CONTINUED)
- --------------------------------------------------------------------------------
In thousands
RETAINED TOTAL
COMMON COMMON PAID-IN UNREALIZED DEFERRED EARNINGS STOCKHOLDERS'
SHARES STOCK CAPITAL GAIN COMPENSATION (DEFICIT) EQUITY
------ ------ --------- ---------- ------------ ---------- -------------
BALANCE - JANUARY 1, 1997 23,749 $ 237 $ 141,941 $ 526 ($5,357) ($ 3,835) $ 133,512
Release of escrow shares related
to 1996 acquisitions -- -- 4,185 -- -- -- 4,185
Issuance of contingent shares
related to 1996 acquisitions 79 1 528 -- -- -- 529
Cancellation of escrow shares (1,164) (11) 11 -- -- -- --
Sale of marketable equity
securities -- -- -- (526) -- -- (526)
Stock options exercised 17 -- 73 -- -- -- 73
Bridge warrants exercised 7 -- 34 -- -- -- 34
Restricted stock issued 202 2 438 -- (440) -- --
Deferred compensation
component of settlement
with former executive officer -- -- -- -- 2,344 -- 2,344
Amortization of deferred
compensation -- -- -- -- 1,261 -- 1,261
Adjustment of income tax
benefit from options exercised -- -- (767) -- -- -- (767)
Warrants issued in connection
with financing agreement -- -- 1,407 -- -- -- 1,407
Net loss -- -- -- -- -- (116,712) (116,712)
------- ----- --------- ----- ------- --------- ---------
BALANCE - DECEMBER 31, 1997 22,890 $ 229 $ 147,850 $-- $(2,192) $(120,547) $ 25,340
======= ===== ========= ===== ======= ========= =========
</TABLE>
The accompanying notes to consolidated financial statements are an integral
part of these statements.
F-6
<PAGE>
<TABLE>
<CAPTION>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
CONSOLIDATED STATEMENTS OF CASH FLOWS
- --------------------------------------------------------------------------------
In thousands
YEARS ENDED DECEMBER 31,
-----------------------------------
1997 1996 1995
--------- --------- ---------
<S> <C> <C> <C>
OPERATING ACTIVITIES
Net income (loss) $(116,712) $ (6,331) $ 3,331
Adjustments to reconcile net income (loss) to net
cash provided by (used in) operating activities:
Asset impairment losses 92,853 390 --
Depreciation and amortization 30,022 11,244 3,003
Bad debt expense 17,630 4,016 577
Deferred income tax provision (benefit) (3,002) (2,814) 582
Stock-based compensation expense 1,261 3,317 235
Amortization of non-cash financing and other costs 239 544 414
Minority interest in income of subsidiaries 2,428 1,576 280
Gain on sale of marketable securities (406) -- --
Loss on settlement of lawsuits 5,739 2,125 --
Settlement with former CEO 1,809 -- --
Loss on sale of fixed assets 225 -- --
Common stock issued to cancel consulting agreement -- 581 --
Common stock issued for settlement of claims -- 779 --
Gain on sale of subsidiary -- (313) --
Loss on sale of subsidiary -- 3,389 --
Gain on extinguishment of debt -- -- (510)
Changes in Assets and Liabilities
(Increase) decrease in:
Accounts receivable (26,991) (10,807) (3,372)
Other receivables (5,622) (2,618) 430
Prepaid expenses 1,063 (1,950) (763)
Other assets 1,452 (1,049) 395
Increase (decrease) in:
Accounts payable and accrued expenses (3,199) 764 398
Minority Interest (Partnership Distributions) (3,470) -- --
Other liabilities (3,158) 3,856 950
--------- --------- ---------
Total adjustments 108,873 13,030 2,619
--------- --------- ---------
NET CASH - OPERATING ACTIVITIES (7,839) 6,699 5,950
--------- --------- ---------
INVESTING ACTIVITIES
Acquisitions, net of cash acquired (21,827) (106,627) (10,218)
Equipment purchases (18,858) (3,807) (1,747)
Payment of purchase price due (5,258) -- --
Sale of marketable equity securities 7,161 (6,425) --
Dispositions, net of cash 1,887 -- --
Investment in subsidiaries (724) (6,732) --
Sale of subsidiaries -- 1,800 --
Pending acquisitions -- (160) 543
--------- --------- ---------
NET CASH- INVESTING ACTIVITIES (37,619) (121,951) (11,422)
--------- --------- ---------
</TABLE>
The accompanying notes to consolidated financial statements are an integral part
of these statements.
F-7
<PAGE>
<TABLE>
<CAPTION>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
- --------------------------------------------------------------------------------
YEARS ENDED DECEMBER 31,
-----------------------------------
1997 1996 1995
--------- --------- ---------
<S> <C> <C> <C>
FINANCING ACTIVITIES
Proceeds from notes payable 78,729 3,937 5,848
Repayments of notes payable and
obligations under capital leases (34,558) (20,480) (8,728)
Common stock issued 106 91,569 9,901
Proceeds from issuance of subordinated convertible debt, net -- 54,493 --
--------- --------- ---------
NET CASH-FINANCING ACTIVITIES 44,277 129,519 7,021
--------- --------- ---------
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS $ (1,181) $ 14,267 $ 1,549
CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR 18,641 4,374 2 ,825
--------- --------- ---------
CASH AND CASH EQUIVALENTS - END OF YEAR $ 17,460 $ 18,641 $ 4,374
========= ========= =========
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the years for:
Interest $ 18,469 $ 5,980 $ 1,181
Income taxes $ 911 $ 3,443 $ 515
</TABLE>
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
The fair market value of common stock and options issued in connection with
acquisitions totaled $4.7 million, $15.4 million and $3.0 million in 1997,
1996 and 1995, respectively.
Restricted common stock with a value of $440,000, $4.9 million and $525,000 in
1997, 1996 and 1995, respectively, was issued for services rendered to the
Company.
Common stock issued in connection with the conversion of debt totaled $763,000
in 1996.
In 1996, warrants issued with Subordinated Convertible Debentures were valued at
$1.7 million.
In 1997, warrants issued with a financing arrangement were valued at $1.4
million.
Capitalized leases were $4.8 million and $9.5 million in 1997 and 1996,
respectively.
In 1995, the Company received medical equipment from a vendor with a value of
$486,000 in exchange for an obligation to purchase medical supplies from
the vendor.
In 1997, the Company acquired the remaining 20% interest in a subsidiary in
exchange for a note payable of $3.1 million.
Information with regard to the Company's acquisitions, all of which are
accounted for under the purchase method of accounting, is as follows (in
thousands):
<TABLE>
<CAPTION>
1997 1996 1995
--------- --------- ---------
<S> <C> <C> <C>
Fair value of non-cash assets acquired, net of liabilities $ 3,492 $ 23,677 $ 9,777
Goodwill 18,335 143,836 11,379
Non-cash consideration paid -- (60,886) (10,938)
--------- --------- ---------
Cash, net of cash acquired $ 21,827 $ 106,627 $ 10,218
========= ========= =========
</TABLE>
The accompanying notes to consolidated financial statements are an integral part
of these statements.
F-8
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
[1] DESCRIPTION OF THE COMPANY
The accompanying consolidated financial statements include the accounts of US
Diagnostic Inc. (formerly U.S. Diagnostic Labs Inc., the "Company"), its
wholly-owned subsidiaries and non-wholly-owned but controlled subsidiaries.
The Company was incorporated in Delaware on June 17, 1993, and is a medical
services provider specializing in the operation and management of multi-modality
diagnostic imaging centers and related medical facilities. As of December 31,
1997, the Company operated 126 centers located throughout the United States. The
Company provides a variety of medical diagnostic testing and evaluation service
procedures including magnetic resonance imaging, computerized tomography
scanning, ultrasound, cardiology and various radiological services.
[2] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
CONSOLIDATION POLICY - The accompanying consolidated financial statements
include the accounts of the Company and its wholly-owned subsidiaries and
non-wholly-owned but controlled subsidiaries. Investments in affiliates which
are not majority owned are reported using the equity method. Significant
intercompany transactions and balances have been eliminated in consolidation.
CASH AND CASH EQUIVALENTS - Cash and cash equivalents are comprised of cash and
certain highly liquid investments with a maturity of three months or less when
purchased. The carrying amount of cash equivalents approximates fair value due
to their short-term nature.
INVESTMENTS IN MARKETABLE EQUITY SECURITIES - Investments in marketable equity
securities are classified as available for sale and reported at fair value.
Unrealized gains and losses, net of tax, are reported as a separate component of
stockholders' equity.
PROPERTY AND EQUIPMENT - Property and equipment are stated at cost. Depreciation
is provided using the straight-line method over the estimated useful lives of
the related assets or the remaining lease term. The equipment used by the
Company is technologically sophisticated and subject to accelerated obsolescence
in the event of significant technological change. Included in property and
equipment are capitalized costs for software and implementation costs paid to
external consultants related to the Company's new billing and general ledger
systems.
INTANGIBLE ASSETS - Intangible assets relate to acquisitions including
investments in unconsolidated subsidiaries accounted for under the equity
method. Goodwill consists of the cost of purchased businesses in excess of the
fair value of net tangible assets acquired. Goodwill is amortized on a
straight-line basis for a period of twenty years. Customer lists and covenants
not to compete are amortized on a straight line basis for a period of ten years
and three to five years, respectively.
Effective January 1, 1996 the Company adopted Statement of Financial Accounting
Standards ("SFAS") No. 121, "Accounting for the Impairment of Long-lived Assets
and for Long-lived Assets to be Disposed of" ("SFAS No. 121") which applies to
long-lived and intangible assets. This statement requires recognition of
impairment losses for long-lived assets whenever the carrying amount of the
assets exceeds the sum of the expected future cash flows associated with such
assets or when events or changes in circumstances indicate that the carrying
amount of an asset may not be recoverable. The measurement of the impairment
losses to be recognized is to be based on the amount by which the carrying value
exceeds the fair market value of the long-lived asset. Fair market value is
determined by using a current market value modeling approach or by evaluating
the current market value of the acquired business using
F-9
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
fundamental analysis. The Company recorded impairment losses in the years ended
December 31, 1997 and 1996 totaling $ 92.9 million and $390,000, respectively.
See also Notes 4 and 5.
NET PATIENT REVENUE - Net patient revenues are reported at the estimated net
realizable amounts from patients, third-party payors and others for services
rendered including estimated prospectively determined adjustments under
reimbursement agreements with third-party payors. These adjustments are accrued
on an estimated basis in the period the related services are rendered and
adjusted in future periods as final settlements are determined.
OTHER REVENUE - Other revenue is primarily comprised of fees charged by the
Company for management services for the technical component of procedures
performed in certain corporate practice of medicine states provided at
non-Company owned imaging facilities. This revenue also includes fees for
management, billing and collection, and marketing. Also included as part of
Other revenue is income generated from the sublease of real property and
equipment.
INCOME TAXES - Deferred tax assets and liabilities are recognized for the future
tax consequences attributable to differences between the financial statement
carrying amounts of existing assets and liabilities and their respective tax
basis. Deferred tax assets and liabilities are measured using enacted tax rates
expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. The effect on deferred tax
assets and liabilities of a change in tax rates is recognized in income in the
period that includes the enactment date.
USE OF ESTIMATES - The preparation of financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and assumptions that affect certain reported amounts of assets, liabilities,
income and expense and disclosures of contingencies. The most significant
estimates relate to contractual and bad debt allowances on accounts receivable,
useful lives of medical equipment, the realizability of long-lived and
intangible assets and reserves for litigation contingencies. Future events could
alter such estimates in the near term. In addition, healthcare industry reforms
and reimbursement practices will continue to impact the Company's operations and
the determination of contractual and other allowance estimates.
EARNINGS (LOSS) PER SHARE - Effective for the Company's consolidated financial
statements for the year ended December 31, 1997, the Company adopted SFAS No.
128, "Earnings Per Share," which replaces the presentation of primary earnings
per share ("EPS") and fully diluted EPS with a presentation of basic EPS and
diluted EPS, respectively. Basic EPS excludes dilution and is computed by
dividing earnings available to common stockholders by the weighted-average
number of common shares outstanding for the period. Similar to fully diluted
EPS, diluted EPS assumes conversion of convertible debt and the issuance of
common stock for all other potentially dilutive equivalent shares outstanding,
unless the effect of issuance would have an anti-dilutive effect. All
prior-period EPS data have been restated. The adoption of this new accounting
standard did not have a material effect on the Company's reported EPS amounts.
STOCK-BASED COMPENSATION PLANS - SFAS No. 123, "Accounting for Stock-Based
Compensation" allows either adoption of a fair value method of accounting for
stock-based compensation plans or continuation of accounting under Accounting
Principles Board ("APB") Opinion No. 25, "Accounting for Stock Issued to
Employees", and related interpretations with supplemental disclosures.
F-10
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
The Company has chosen to account for all stock-based compensation arrangements
under which employees receive shares of its stock under APB Opinion No. 25 with
related disclosures under SFAS No. 123. Pro forma net earnings (loss) per common
share amounts as if the fair value method had been adopted are presented in Note
12.
FAIR VALUE OF FINANCIAL INSTRUMENTS - SFAS No. 107, "Disclosure About Fair Value
of Financial Instruments" requires companies to disclose the fair value of
financial instruments. Management believes that the carrying values of its
financial instruments approximates their fair values and any differences which
may exist between the carrying values and fair values are not material.
RECENT ACCOUNTING PRONOUNCEMENTS - SFAS No. 129, "Disclosure of Information
About Capital Structure" requires an entity to provide certain disclosures
within its financial statements about the pertinent rights and privileges of the
various securities outstanding for fiscal years beginning after December 15,
1997. The Company believes SFAS No. 129 will have little, if any, effect on the
information already disclosed in the Company's financial statements.
SFAS No. 130, "Reporting Comprehensive Income", requires an entity to report
comprehensive income and its components for fiscal years beginning after
December 15, 1997. The Company believes SFAS No. 130 will have little, if any,
effect on the information already disclosed in the Company's financial
statements.
SFAS No. 131, "Disclosures About Segments of an Enterprise and Related
Information" requires an entity to report financial and descriptive information
about its reportable operating segments for fiscal years beginning after
December 15, 1997. The Company believes SFAS No. 131 will have little, if any,
effect on the information already disclosed in the Company's financial
statements.
STATEMENT OF POSITION 98-1, "Accounting for the Costs of Computer Software
Developed or Obtained for Internal Use", requires an entity to expense all
software development costs incurred in the preliminary project stage training
costs and data conversion costs for fiscal years beginning after December 15,
1998. The Company believes that this statement will not have a material effect
on the Company's accounting for computer software acquisitions.
RECLASSIFICATIONS - Certain prior year amounts in the financial statements have
been reclassified to conform with the current year presentation.
[3] PROPERTY AND EQUIPMENT
A summary of property and equipment at December 31, is as follows:
In thousands
ESTIMATED
1997 1996 USEFUL LIFE
--------- -------- -----------
Land $ 1,868 $ 1,118
Buildings 7,131 5,490 40 Years
Medical equipment 83,273 63,207 7 Years
Furniture and fixtures 3,539 3,451 7-10 Years
Office, data processing equipment
and software 10,994 6,773 3-10 Years
Leasehold improvements 10,092 11,732 10 Years
-------- --------
Total 116,897 91,771
Less: accumulated depreciation
and amortization (25,330) (11,825)
--------- --------
Property and equipment, net $ 91,567 $ 79,946
========= ========
F-11
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
Included in property and equipment is equipment under capital leases amounting
to $31.8 million and $26.0 million at December 31, 1997 and 1996, respectively.
Depreciation expense amounted to $19.2 million, $6.6 million and $2.2 million
for the years ended December 31, 1997, 1996 and 1995, respectively, of which
$4.3 million, $1.5 million and $1.2 million was attributed to the equipment
under capital leases.
[4] INTANGIBLE ASSETS
A summary of intangible assets at December 31, is as follows:
In thousands
ESTIMATED
1997 1996 USEFUL LIFE
-------- --------- -----------
Goodwill $ 111,220 $ 157,404 20 years
Covenants not to compete 3,142 5,852 3-5 years
Customer lists 3,189 4,640 10 years
Other intangibles 237 678 3-5 years
--------- ---------
Total 117,788 168,574
Less accumulated amortization (13,890) (4,899)
--------- ---------
Intangibles, net $ 103,898 $ 163,675
========= =========
A roll-forward of intangible assets for the two years ended December 31, is as
follows:
<TABLE>
<CAPTION>
In thousands
1997 1996
--------- ---------
<S> <C> <C>
Beginning Intangibles, net $ 163,675 $ 17,993
Intangible assets recorded as a result of acquisitions 18,335 148,063
Increases due to earn outs and minority interest purchases 7,861 --
Subsequent purchase accounting adjustments to intangible assets, net 1,324 2,268
Impairment losses (see notes 2 and 5) (75,980) --
Amortization (10,611) (4,649)
Decreases due to dispositions (706) --
--------- ---------
Ending Intangibles, net $ 103,898 $ 163,675
========= =========
</TABLE>
[5] ASSET IMPAIRMENT LOSSES
The majority of acquired businesses and imaging centers which comprise the
Company were purchased in 1996. As a result, 1997 was the first year of
uninterrupted operation for such acquired entities as a part of the Company's
consolidated group. During 1997, current management became aware that many of
the acquired centers were not performing as originally projected.
F-12
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
At year-end all acquired businesses were analyzed in depth, in light of the
additional operating data during the period of the Company's ownership, to
determine whether such shortfalls in performance were of a temporary nature and
if current and expected future operating income would be sufficient to cover
annual amortization of intangible and long-lived assets acquired (see Note 2).
Management has recorded impairment losses for those centers for which the sum of
the expected future cash flows does not cover the carrying value of the assets
acquired. Management is currently investigating the causes of such performance
shortfalls including, in some cases, to what extent the impairment losses are a
result of misrepresentations by sellers. The components of the 1997 impairment
loss of $92.9 million are as follows:
In thousands
<TABLE>
<CAPTION>
<S> <C>
Intangible assets $75,980
Investment in unconsolidated subsidiaries accounted for
using the equity method (primarily intangible assets included therein) 6,269
Property and equipment 4,609
Acquired receivables 4,817
Other long-lived assets 1,178
-------
Total impairment losses $92,853
=======
</TABLE>
[6] LONG-TERM DEBT
Long-term debt at December 31 consists of the following (see also Note 7):
<TABLE>
<CAPTION>
In thousands
1997 1996
------- -----
<S> <C> <C>
Revolving credit loan, up to $35 million maximum, interest at prime
plus 2%, due February 1999. Collateralized by accounts receivable $35,000 $ --
Acquisition and equipment line of credit, up to $25 million maximum, interest at
10% to 11%, due in monthly installments
through 2002. Collateralized by equipment 12,250 --
10% to 11% term loans to lending institution, up to $15 million
maximum, due through 2002. Collateralized by equipment 15,000 --
6 1/2% convertible note, discounted to yield 9%, due in June 2001 9,296 9,210
Other convertible notes with stated interest rates ranging from
6% to 7%, discounted to yield 9%, maturing through March 2001 1,364 5,146
6% to 14% notes payable to lending institutions, due in monthly
installments through March 2004. Collateralized by medical
equipment 42,841 32,914
F-13
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
6% to 9.75% notes payable related to acquisitions, due in monthly
installments through August 2000. Collateralized by
substantially all assets of the companies acquired 21,838 22,425
--------- --------
Total 137,589 69,695
Less: current portion (18,590) (27,336)
--------- --------
Total Long-Term debt $ 118,999 $ 42,359
========= ========
</TABLE>
At December 31, 1997, aggregate maturities of long-term debt, not including
subordinated convertible debentures, were as follows:
In thousands
1998 $ 18,590
1999 57,239
2000 19,308
2001 29,129
2002 9,990
Thereafter 3,333
---------
$ 137,589
=========
In February 1997, the Company entered into a financing agreement with DVI
Business Credit Corporation ("DVIBC") to provide two credit facilities of $25
million each (one of which was increased to $35 million on September 30, 1997 -
see discussion below). Borrowings are subject to certain conditions such as the
availability of unencumbered assets to collateralize advances and maintenance of
at least $5 million in cash during all reporting periods. The first $25 million
is a revolving credit loan from DVIBC secured by accounts receivable. The second
$25 million is an acquisition and equipment line of credit from DVI Financial
Services Inc. ("DVIFS"). Advance of funds on the second $25 million line is
based upon a review by DVIFS of the entity acquired and/or a review of the
assets securing the loan. The Company borrowed $25 million under the revolving
credit loan in February 1997, which will become due on February 28, 1999 (which
maturity date was extended to February 28, 2000 on March 31, 1998), and bears
interest, payable monthly, at prime plus two percent (10.5% at December 31,
1997). Between March 1997 and December 31, 1997, the Company borrowed a total of
$12.25 million, collateralized by equipment, under the second $25 million line.
Each such advance is repayable through 2002 in sixty monthly installments with
interest at 10% to 11%.
At the time the Company entered into the financing arrangement with DVIBC, DVIBC
believed that a portion of the Company's accounts receivable did not meet
certain of the lender's eligibility criteria under the line of credit. DVIBC
granted the Company a waiver with respect to such criteria but provided in the
loan agreement that if the Company did not satisfy such criteria to DVIBC's
satisfaction within 90 days of the original funding of the loan, DVIBC had the
right to declare the nonconforming accounts ineligible and exclude them from the
borrowing base, in which case the Company would have been obligated to reduce
its then existing indebtedness to DVIBC to the borrowing base level at such
time. DVIBC has granted the Company additional waivers of such criteria through
December 31, 1998. However, if DVIBC continues in this belief and if the Company
is not able to satisfy such criteria on or before December 31, 1998 and does not
obtain any further waiver thereof from DVIBC, the Company may be required to pay
down its then outstanding accounts
F-14
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
receivable loans from DVIBC to a level not in excess of the Borrowing Base on
such date. There can be no assurance that the Company will be able to satisfy
such eligibility criteria on or before December 31, 1998, and if it is unable to
do so, it may not have funds on hand sufficient to make the required payment of
the DVIBC indebtedness. If the Company fails to make any such required payment,
it could be declared in default under the DVIBC loan agreement, as well as under
the DVIFS arrangement described below and under the Company's Debenture (see
Note 7), resulting in possible debt acceleration from both lenders. If the
Company is unable to draw upon such credit facilities or to replace the same
without delay, the Company's liquidity would be seriously impaired.
On September 29, 1997, the Company and its wholly-owned subsidiary, Medical
Diagnostics, Inc. ("MDI"), entered into a series of Loan and Security Agreements
with DVIFS pursuant to which DVIFS agreed to provide term loans to MDI, in the
aggregate not to exceed $15 million, the repayment of which is guaranteed by the
Company and secured by all of the outstanding shares of MDI and by liens on
equipment of MDI, principally consisting of MRI machines and computer equipment.
Each advance under the term loans is repayable in 60 equal monthly installments
inclusive of principal and interest at the rate of 10% per annum as to the first
$7.5 million borrowed and 11% per annum as to any additional amounts borrowed.
In addition, the Company may be required to pay down portions of these
outstanding term loans with the proceeds it receives as a result of
reimbursement or indemnification in connection with the shareholder litigation
described in Note 20.
As of December 31, 1997, $15 million had been borrowed under this arrangement.
In addition, in connection with the term loans, the Company (i) increased its
revolving credit loan from $25 million to $35 million (ii) extended the maturity
date of the revolving credit loan from February 28, 1998 to February 28, 1999
(which maturity date was extended to February 28, 2000 on March 31, 1998), and
(iii) issued to DVI two warrants to purchase an aggregate of 250,000 shares of
Common Stock of the Company at an exercise price of $7.6875 per share, which was
the fair market value of a share of such Common Stock on the date the warrants
were issued. One of the warrants to purchase 125,000 shares of Common Stock is
exercisable immediately, and a second warrant to purchase 125,000 shares of
Common Stock is exercisable beginning on or after April 30, 1998 but only if the
entire indebtedness to DVIFS and DVIBC has not been reduced by at least $12.5
million (exclusive of regularly scheduled amortization) prior to the date of
exercise. Both of the warrants expire on September 30, 2004. The estimated fair
value of the warrants were $1.4 million as of the date of issuance. This amount
is being amortized to interest expense over the term of the related
indebtedness. The unamortized balance at December 31, 1997 is $1.3 million, and
is offset against long-term debt in the accompanying consolidated balance sheet.
As further discussed in Note 22, in March 1998 the Company entered into a
definitive agreement to sell MDI. The proceeds will be used in part to reduce
certain DVI debt.
On January 20, 1998, Michael O'Hanlon, the President of DVI, Inc., an affiliate
of DVIFS and DVIBC, was elected to the Board of Directors of the Company. See
Note 21.
The 6 1/2% Convertible Note (the "Note") was originally issued to HEICO
Corporation ("HEICO") in 1996, and as subsequently modified on September 10,
1997, as partial consideration for the Company's acquisition of all of the
outstanding stock of MediTek Health Corporation from HEICO (see Note 21). The
Note was convertible into the Company's Common Stock at $9.25 per share for an
aggregate of 1,081,081 shares. The Note may be prepaid, at its $10 million face
value, upon 60 days written notice, by the Company after December 31, 1997. The
Company can require the holder to convert the Note at the conversion price if
the last sale price of the Common Stock averages at least $9.25 per share for
the ten trading days immediately preceding the
F-15
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
"required conversion date". The "required conversion date" is any time
commencing on the later of December 31, 1997 (January 1, 1999 as modified on
September 10, 1997) or the date that the shares of Common Stock into which the
Note is convertible are registered for resale by the Company under the
Securities Act of 1933. The Company granted to the holder of the Note
registration rights to the Common Stock into which the Note is convertible.
Until such time as the shares are registered, the holder may require the Company
to redeem the Note for cash at its face value of $10 million. The Note balance
of $9.2 million, net of unamortized discount of $790,000, was included in the
current portion of long-term debt at December 31, 1996.
On September 10, 1997, the conversion price per share was reduced from $9.25 per
share to $8.50 per share, in consideration of deferring the demand feature of
the Note. As amended, the Note is convertible into the Company's Common Stock at
$8.50 per share or an aggregate of 1,176,472 shares, matures on June 30, 2001,
and may be redeemed by the holder starting January 1, 1999 if the shares into
which the note is convertible have not by that time been registered under the
Securities Act. On September 16, 1997, HEICO sold the Note to Forum Capital
Markets L.P. ("Forum"). C. Keith Hartley, a director of the Company, is a
managing director of Forum. On September 16, 1997, Forum resold the Note to
eighteen (18) individual parties in various amounts totaling $10 million,
resulting in the Company re-issuing separate Notes to each of the purchasers for
their respective amounts. Each individual Note contains the same terms and
conditions as the amended Note that HEICO sold to Forum. In November, 1997, the
Company listed a global note for trading on the PORTAL Market; and the Company
is giving holders that qualify as Qualified Institutional Buyers (as defined
under Rule 144A of the Securities Act of 1933) the opportunity to exchange their
Notes for an interest in a global note to be held by the Depository Trust
Company in accordance with its book entry system.
The Other Convertible Notes are convertible into shares of Common Stock at an
average conversion price of $5.45 per share or 278,018 shares as of December 31,
1997.
[7] SUBORDINATED CONVERTIBLE DEBENTURES
In 1996, the Company consummated a $57.5 million offering of 9% Subordinated
Convertible Debentures (the "Debentures") due in 2003. Holders of the Debentures
are entitled to convert 100% of the principal amount into Common Stock of the
Company at a conversion price of $9.00 per share. The conversion price is
subject to adjustment under certain circumstances as described in the Debenture
Indenture ("Indenture"). The Company may not redeem the Debentures, in whole or
in part at any time prior to March 31, 1999. Thereafter, the Debentures are
redeemable at certain redemption prices as set forth in the Indenture. In the
event of a "change of control" as defined in the Indenture, the Company must
offer to repurchase each holder's Debenture at a purchase price equal to 100% of
the principal amount, plus accrued interest.
Warrants to acquire 319,445 shares of the Company's Common Stock at $9.00 per
share were issued to the underwriter of the offering of the Debentures (See
Notes 2 and 21). The estimated fair value of the warrants at the date of the
offering was $1.7 million. This amount is being amortized to interest expense
over the term of the related Debentures. The unamortized balance at December 31,
1997 and 1996 is $1.2 million and $1.5 million respectively, and is offset
against long-term debt in the accompanying consolidated balance sheet.
Pursuant to the Indenture, the Company is required to maintain consolidated net
worth of at least $18 million. In the event that the Company's consolidated net
worth at the end of two consecutive fiscal quarters is below $18 million, the
Company must offer to repurchase 12.5% of the aggregate principal
F-16
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
amount of Debentures originally issued (or lesser amount outstanding at the time
of the deficiency). Under certain covenants of the Indenture, the Company is
limited in the amount of debt, as defined, it may incur. The Company and its
subsidiaries may generally incur debt, as defined, if the ratio of Debt to
Operating Cash Flow, of the Company and its subsidiaries after giving pro forma
effect to such debt is 6.5 to 1 or less.
In March 1998, the Company determined that it was not in compliance with the
Indenture's Debt to Operating Cash Flow Ratio in the fourth quarter of 1997. The
non-compliance was due to the required treatment of certain items in the ratio
calculation relating to significant non-operating write-offs, reserves and
expenses taken by the Company in 1996 and 1997 for various items including the
settlement of shareholder class action claims, the previously disclosed NASDAQ
and SEC proceedings and related legal and accounting professional services fees
totaling approximately $10 million. The Company obtained the consent of a
majority of the holders of outstanding Debentures to waive any non-compliance in
the fourth quarter of 1997 and permit the Company to modify the Indenture to add
back $10 million representing the above noted items to the Operating Cash Flow
calculation for each quarter ended March 31, 1998, June 30, 1998 and September
30, 1998 (the "Consent").
Based upon the receipt of the Consent, the Company was in compliance with the
Debt to Operating Cash Flow Ratio during the first quarter of 1998.
The Indenture also prohibits the Company from paying any dividends on Common
Stock. In addition, the Indenture requires that the Company and its subsidiaries
engage solely in the acquisition, operation and management of multi-modality
diagnostic imaging centers and other medical service facilities.
Debenture issuance costs of $3.5 million are being amortized as interest expense
over the term of the related Debentures. The unamortized balance at December 31,
1997 and 1996 is $2.6 million and $3.1 million, respectively, and is included in
other assets in the accompanying consolidated balance sheet.
[8] OBLIGATIONS UNDER CAPITAL LEASES
Obligations under capital leases are stated on the accompanying consolidated
balance sheet at the present value of future minimum lease payments. Interest
rates on capital leases ranged primarily between 7 1/2% and 13%.
F-17
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
Future minimum lease payments under capital leases, together with the present
value of minimum lease payments subsequent to December 31, 1997, are as follows:
In thousands
DATE AMOUNT
---- ---------
1998 $ 10,567
1999 7,269
2000 3,528
2001 1,572
2002 242
Thereafter --
--------
Total 23,178
Less: amount representing interest (2,450)
--------
Total 20,728
Less: current portion (9,155)
--------
Long-term portion $ 11,573
========
[9] INCOME TAXES
The provision (benefit) for income taxes shown in the consolidated statements of
operations consist of the following:
In thousands
1997 1996 1995
------- ------- -------
CURRENT
Federal $ 115 $ 1,765 $ 123
State 1,048 448 25
------- ------- -------
1,163 2,213 148
------- ------- -------
DEFERRED
Federal (2,600) (2,243) 494
State (402) (570) 87
------- ------- -------
(3,002) (2,813) 581
------- ------- -------
TOTAL $(1,839) $ (600) $ 729
======= ======= =======
F-18
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
The difference between the effective income tax rate and the federal income tax
rate is summarized as follows:
1997 1996 1995
----- ---- ----
Federal tax rate 34% 34% 34%
Impairment of non-deductible intangible assets (17) -- --
Non-deductible amortization of intangible assets (2) (10) --
Increase in valuation allowance (12) -- --
Minority interest -- (2) (3)
State taxes, net of federal benefit (1) (4) (3)
Non-deductible capitalized costs -- (16) --
Carry-forwards benefited -- 2 (15)
Extraordinary item -- -- 6
Other -- 5 3
--- --- ---
Effective tax rate 2% 9% 22%
=== === ===
Significant components of the Company's deferred tax assets and liabilities at
December 31, 1997 and 1996 are as follows:
In thousands
CURRENT 1997 1996
- ------- -------- -------
Deferred tax assets:
Allowance for bad debts $ 3,905 $ 627
Other allowances and reserves 1,648 2,973
Deferred tax liabilities:
Cash to accrual differences on acquired entities (929) (1,488)
Valuation allowance (4,624) (2,000)
-------- --------
Net current deferred tax assets 0 112
NON-CURRENT
- ------------
Deferred tax assets:
Net operating losses 15,074 8,775
Basis differences of intangible assets 5,091 2,618
Compensatory options 326 591
Asset impairment 11,135 --
Other 2,082 669
Deferred tax liabilities:
Equipment basis differences (7,632) (6,139)
Cash to accrual differences (929) (2,975)
Unrealized gain on investments -- (329)
Other (386) (253)
Valuation allowance (24,761) (9,641)
-------- --------
Net non-current deferred tax liability 0 (6,684)
-------- --------
Net deferred income tax liability $ 0 $ (6,572)
======== ========
F-19
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
The Company has operating loss carryforwards of approximately $44.3 million
expiring through the year 2011. Approximately $22.3 million of the operating
loss carryforwards relate to acquired entities (see Note 11). The utilization of
the acquired loss carryforwards is limited to approximately $3.3 million per
year. Due to the Company's recent history of significant losses, management has
provided a valuation allowance for the net deferred tax asset as realization is
not more likely than not. Any future reduction in the valuation allowance due to
the utilization of net operating losses and realization of deferred tax assets
of acquired entities will reduce goodwill to the extent available and then
income tax expense.
[10] CAPITAL TRANSACTIONS
In connection with the Company's initial public offering in 1994, all of the
Company's stockholders at that time entered into an escrow agreement pursuant to
which they placed into escrow 1,163,853 shares (the "IPO Escrow Shares") of the
Company's Common Stock owned by them. Because the Company did not meet specified
minimum income goals, all of the IPO Escrow Shares were canceled in early 1997.
The IPO Escrow Shares are included in authorized, issued and outstanding shares
on December 31, 1996. As of December 31, 1996, the Company had 991,785 shares of
its common stock in escrow relating to companies acquired, to be released to the
former owners of the companies acquired upon the achievement of certain earnings
in future periods (see Note 13). During fiscal 1997, earnings targets were
achieved for certain companies, and 720,785 of such shares were released from
escrow. Additionally, 79,135 shares were issued during 1997 related to such
earnings targets for one of its acquisitions. As of December 31, 1997, 271,000
shares remain in escrow, pending achievement of specified earnings.
In connection with the Company's public stock offerings in 1994 and 1995, a
total of 4,237,250 Class A Warrants (including 425,000 warrants issued in
connection with a $850,000 bridge financing in 1995) and 3,812,250 Class B
Warrants were issued. The Class A Warrants entitled each registered holder to
purchase one share of Common Stock and one Class B Warrant at an exercise price
of $6.25. The Class B Warrants entitled each registered holder to purchase one
share of Common Stock at an exercise price of $8.00. In 1996, in accordance with
the terms of the warrants, the Company called for the redemption of all of the
outstanding Class A and Class B Warrants. As a result, in 1996, substantially
all of the registered holders of Class A and Class B Warrants exercised their
warrants. The Company received $90.5 million in proceeds from the exercise (net
of fees to the IPO underwriter of $2.2 million). There were no Class A or Class
B Warrants outstanding at December 31, 1996.
In 1995, 50,000 shares of restricted Common Stock were issued to each of the
Company's former Chief Executive Officer (replaced in March 1997, See Note 19),
the Company's former President and to Coyote Consulting and Financial Services,
LLC ("Coyote Consulting" - See Notes 19 and 20) in connection with the Company's
1995 Long-Term Incentive Plan. These 150,000 restricted shares were recorded by
the Company as a deferred charge in the amount of $525,000 in 1995 and are being
amortized over the two year vesting period of the restricted stock. The
unamortized portion pertaining to Coyote Consulting and the Company's former
President were expensed in 1996 (See Note 12).
In December 1996, the Company and Jeffrey Goffman, who was at the time the
Company's Chief Executive Officer, entered into a Settlement Agreement with
Consolidated General Ltd., U.K. Errington Ltd., and certain other persons
(collectively, the "Claimants"). Under the Settlement Agreement, the Company
issued an aggregate of 68,400 shares of its Common Stock, with a fair market
value of $654,000 at the date of issuance, to the Claimants and paid to the
Claimants an aggregate of $1.3 million in cash. In exchange, the Claimants
executed general releases in favor of the Company and Mr.
F-20
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
Goffman. Under the Settlement Agreement, the Claimants settled claims relating
to allegations that they had escrowed too many shares of their Common Stock
under the escrow agreement entered into in connection with the Company's initial
public offering. The Claimants also released their claims relating to promissory
notes in the aggregate principal amount of $850,000 executed by Mr. Goffman in
favor of the Claimants, which promissory notes were collateralized by 150,000
shares of the Company's Common Stock owned by Mr. Goffman. After the execution
of these promissory notes, Mr. Goffman executed an assignment and assumption
agreement on behalf of himself and the Company, under which the Company
purportedly assumed Mr. Goffman's obligations under such promissory notes. These
promissory notes were executed by Mr. Goffman in payment of consideration to the
Claimants under consulting agreements between Mr. Goffman and the Claimants,
which Mr. Goffman asserted were entered into by him for the benefit of the
Company. Under the terms of these consulting agreements, the Claimants were to
provide consulting and advisory services to Mr. Goffman, purportedly on behalf
of the Company, to assist in funding, evaluating and structuring business
opportunities and transactions. The fair market value of the shares issued and
the cash paid totaled $2 million and is included in loss on settlement of claims
in the accompanying 1996 consolidated statements of operations. Subsequently,
the Claimants alleged that the Company had not registered the aforementioned
68,400 shares of Common Stock by the date contemplated in the December 1996
Settlement Agreement and made claims against the Company. The dispute was
settled as to Consolidated in November 1997 and as to Errington in January 1998
by payment by the Company to the Claimants of a total of approximately $364,000
to settle all additional claims and the Company was released from any further
liability under the December 1996 Settlement Agreement. The settlement amount
was expensed in the accompanying 1997 consolidated statement of operations.
In 1996, 149,030 shares of the Company's Common Stock were issued upon
conversion of convertible debt securities in accordance with the conversion
terms.
In connection with a settlement agreement, dated January 30, 1996, the Company
issued 20,000 shares of Common Stock in consideration for the alleged improper
termination of employment and cancellation of options to purchase 40,000 shares
of the Company's Common Stock. The aggregate market value of these 20,000 shares
of Common Stock was approximately $125,000 and is included in loss on settlement
of claims during 1996 in the accompanying consolidated statement of operations.
A former director of the Company is one of three stockholders of Med LNC, Inc.,
to which the Company was obligated to pay monthly consulting fees of $15,000
through June 1999. This consulting agreement was entered into in conjunction
with an acquisition. In January 1996, the Company issued 93,000 shares of Common
Stock in full payment of the remaining 41 months of the agreement. The aggregate
market value of the stock issued was $581,000 at the date the shares were
issued. This amount is included in general and administrative expense during
1996 in the accompanying consolidated statements of operations.
In March 1997, the Company granted options to acquire 100,000 shares of the
Company's common stock to its then Chairman of the Board and options to acquire
35,000 shares of the Company's common stock to each of two directors. The three
Directors comprised the Special Committee appointed by the Company's Board of
Directors to review the Company's prior relationship with Coyote Consulting and
Keith Greenberg (See Note 19). The options vested on September 30, 1997. The
exercise price of the options is $8.625 which was the market value of the
Company's common stock at the date of grant.
On April 23, 1997 the Company granted options to purchase 200,000 shares of the
Company's common stock to its current Chief Executive Officer and options to
purchase 30,000 shares of the Company's
F-21
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
common stock to its former Chief Financial Officer. The exercise price of the
options is $6.25, which was the market value of the Company's common stock at
the date of grant. The Company also granted options to purchase 50,000 shares of
the Company's common stock to its new Chief Financial Officer. The exercise
price is $6.6875, the market value of the Company's common stock at date of
employment, June 18, 1997. All these options vest in equal annual amounts over a
three-year period commencing one year from date of grant.
Prior to January 1997, the Company granted contractual rights to certain persons
to whom the Company issued securities to register such securities under the
Securities Act of 1933, and state securities registration statutes, and in some
instances the Company agreed to repurchase the stock issued to these persons or
to pay specified liquidated damages if such registration was not effected in a
timely manner. The Company's inadvertent failure to timely file a Form 8-K
report in connection with one of its 1996 acquisitions made it impracticable for
the Company to file registration statements under the Securities Act of 1933
until June 1998. As such, the Company had not registered certain securities in
accordance with provisions of various registration rights agreements. In
November 1997 and January 1998 the Company entered into settlement agreements
with two of the holders of such registration rights who had received a total of
68,400 shares of Common Stock as part of an earlier settlement with the Company
in December 1996. Pursuant to the November 1997 and January 1998 settlements
pertaining to registrations, the Company paid an aggregate of $364,000 in
December 1997 and February 1998 in full and final satisfaction of its
registration and any other obligations. Such amount is included in general and
administrative expense in the accompanying 1997 consolidated statement of
operations. Another individual who asserted an agreement to register securities
has requested and received a commitment to provide piggyback registration rights
for 50,000 shares of the Company's Common Stock, at no cost to the Company, in
full satisfaction of the Company's registration obligations, if any.
The only other parties to assert non-compliance with an agreement to register
the Company's Common Stock is a group of sellers of centers in Pennsylvania and
certain sellers of centers in New York who have brought suit against the Company
as more fully described in Note 20.
The Company's financial condition may also be materially adversely affected to
the extent that persons to whom the Company has issued securities successfully
assert claims against the Company based upon inadequacy of disclosure regarding
the background of Keith Greenberg, as more fully discussed in Note 20. In
addition to the class action lawsuits which have been settled in principal, two
such suits have been brought to date. Each lawsuit is more specifically
described in Note 20.
At December 31, 1997, the Company had 22,889,633 shares of Common Stock issued
and outstanding.
A summary of Shares of Common Stock reserved for potential future issuance as of
December 31, 1997, is as follows (in thousands of shares):
$57.5 million subordinated convertible debentures 6,389
Stock option plans 3,111
Underwriter options and warrants 1,645
$10.0 million convertible note 1,176
Warrants issued to lender 250
Warrants outside of stock option plans 625
Other convertible debt 278
1996 restricted stock grants not yet issued 228
Bridge warrants 53
------
13,755
======
F-22
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
As the Company previously disclosed, on July 3, 1997 a NASDAQ Listing
Qualifications Panel determined that the Company was not in compliance with the
net tangible assets test for continued listing on the NASDAQ National Market
System, but determined after a hearing to grant the Company a waiver.
Accordingly, while the Company does not presently meet all of the NASDAQ's
continued listing criteria, the Company's securities remain listed on the NASDAQ
National Market System pursuant to the waiver. NASDAQ has informed the Company
that it will continue to monitor the Company's progress, and that it reserves
the right, in the event there is a material change in the Company's operational
or financial structure or character, to re-examine the appropriateness of the
waiver.
There can be no assurance that, if NASDAQ determines in the future that the
Company's net tangible asset waiver is no longer effective, the Company will be
able to meet the requirement for continued listing under NASDAQ's current
listing standards of $5 per share minimum bid price contained in the new
alternative listing standards (absent the occurrence of certain events such as
a reverse stock split).
[11] ACQUISITIONS
All of the acquisitions made by the Company during the three years ended
December 31, 1997, were accounted for under the purchase method of accounting.
The Company allocates the purchase price to net assets acquired based upon their
estimated fair market values. During the initial year after acquisition the
Company may adjust the allocation of the purchase price subsequent to the
initial allocation as more information becomes available.
During 1995, the Company and its subsidiaries acquired 12 multi-modality
diagnostic imaging businesses. The combined purchase price for the businesses
was $21.9 million. The purchase price was comprised of $10.9 million in cash,
$8.0 million of debt and shares of Company's common stock with an aggregate
market value of $3.0 million at the respective valuation dates of the
acquisitions. The excess of the purchase price over the fair value of net assets
acquired relating to these acquisitions totaled $11.4 million.
During 1996, the Company and its subsidiaries acquired at least a majority
interest in 22 multi-modality diagnostic businesses. The combined purchase price
for the businesses was $174.9 million. The purchase price was comprised of
$122.3 million in cash (of which $8.4 million and $2.5 million was unpaid at
December 31, 1996 and 1997, respectively), $37.2 million in debt, and common
stock and options of the Company with an aggregate market value of $15.4 million
at the respective valuation dates of the acquisitions. The excess of the
purchase price over the fair value of net tangible assets acquired relating to
these acquisitions totaled $143.8 million.
During 1997, the only acquisition made by the Company was Medical Diagnostics,
Inc. in the first fiscal quarter. Total consideration paid was approximately $22
million in cash and assumption of debt of $8.6 million. MDI provides fixed and
mobile diagnostic imaging services to approximately 40 hospitals. As further
discussed in Note 22, in March 1998 the Company entered into a definitive
agreement to sell MDI.
Certain of the above acquisition agreements provide for contingent consideration
upon the achievement of certain earnings in future periods by the acquired
company. When and if the consideration is paid,
F-23
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
goodwill is increased by the amount of the additional consideration, and is
amortized on a prospective basis over its remaining estimated life, subject to
review of impairment. See Notes 2 and 5.
There can be no assurance that, if NASDAQ determines in the future that the
Company's net tangible asset waiver is no longer effective, the Company will be
able to meet the requirements for continued listing under NASDAQ's current
listing standards of $5 per share minimum bid price contained in the new
alternative listing standards (absent the occurrence of certain events such as
a reverse stock split).
In connection with a 1996 acquisition, the Company guaranteed to repurchase
206,000 shares of the Company's common stock issued to the sellers if, on the
last trading day prior to the second anniversary of the closing date (as
defined), the market price of the Company's common stock is more than $2.00
below a defined price. The Company placed 103,000 of these shares into escrow,
which were released in late 1997 when certain earnings targets were met. The
Company's share price was more than $2.00 below the defined price as of the
specified date, resulting in a liability to repurchase the common shares at a
total price of approximately $1.9 million. The Company has an agreement in
principle with the sellers, subject to execution of a definitive agreement by
both parties, for payment over 36 equal installments plus interest at 7%. The
Company is presently negotiating with the sellers to extend the payment period.
As of December 31, 1997, the Company had recorded $1,204,000 ($825,000 in 1996
and $379,000 in 1997) in paid-in capital to reflect the market price as of the
date earned of the 206,000 shares and recorded a "purchase price due on
companies acquired" of approximately $694,000 (representing the difference
between amount to be paid of $1.9 million and the value of the shares to be
repurchased). As a result, goodwill of $1,900,000 was recorded. Once the
agreement with the seller is accepted and the escrowed shares are returned, the
Company will reduce paid-in capital and increase "purchase price due on
companies acquired" by $1,204,000.
In connection with the aforementioned acquisitions, the Company entered into
consulting and employment contracts with certain individuals of the acquired
companies. Payments relating to these contracts are charged to operations in the
period in which the related services are provided.
The Company also entered into non-compete agreements with certain individuals of
some of the companies acquired. The cost of these non-compete agreements is
recorded as an intangible asset as of the date of the related acquisition and
amortized over the contractual life of the agreement.
The results of operations of the acquired businesses are included in the
Company's consolidated results of operations from the date of acquisition.
F-24
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
The following summarizes the unaudited pro forma effect of the businesses
acquired in 1997, 1996 and 1995, accounted for under the purchase method as if
the businesses had been acquired as of January 1, 1995. This presentation is
prepared in accordance with APB Opinion No. 16 and does not reflect estimates
for potential operating efficiencies and other cost savings.
<TABLE>
<CAPTION>
UNAUDITED:
1997 1996 1995
--------- ----------- -----------
In thousands
<S> <C> <C> <C>
Revenue as reported $ 216,222 $ 102,061 29,416
Effect of acquisitions 3,316 116,202 177,712
--------- ----------- -----------
Pro Forma revenue $ 219,538 $ 218,263 $ 207,128
========= =========== ===========
Net income (loss) as reported $(116,712) $ (6,331) 3,331
Effect of acquisitions (395) 1,567 79
--------- ----------- -----------
Pro Forma net income (loss) $ 117,107 $ (4,764) 3,410
========= =========== ===========
Earnings Per Share
Basic:
Historical $ (5.26) $ (.48) $ .77
Effect of acquisitions (.02) .12 .02
--------- ----------- -----------
Pro Forma net income (loss) $ (5.28) $ (.36) $ .79
========= =========== ===========
Diluted:
Historical $ (5.26) $ (.48) $ .70
Effect of acquisitions (.02) .12 .01
========= =========== ===========
Pro Forma net income (loss) $ (5.28) $ (.36) $ .71
========= =========== ===========
</TABLE>
[12] STOCK OPTION PLANS AND WARRANTS
At December 31, 1997, the Company has two stock-based compensation plans. In
accordance with SFAS No. 123 "Accounting for Stock-Based Compensation", ("SFAS
No. 123"), the Company has accounted for all stock-based grants issued to
non-employees subsequent to December 15, 1995 as provided for by SFAS No. 123.
The Company has elected to continue to account for its stock-based grants to
employees and directors in accordance with the provisions of APB Opinion No. 25
"Accounting for Stock Issued to Employees". The fair value of each option
granted to non-employees and employees is estimated on the date of grant using
the Black-Scholes option-pricing model with the following weighted-average
assumptions for 1995, 1996, and 1997, respectively: risk-free interest rates
ranging from 5.8 percent through 7.1 percent for 1995 and 1996, and 5.7 percent
to 6.6 percent for 1997; dividend yield of zero percent for all years; expected
lives ranging from 4 to 7 years for 1995 and 1996, and 3 to 6 years for 1997;
and volatility of 73 percent for 1995 and 1996, and 82 percent for 1997.
Compensation cost charged to operations in connection with the Company's
stock-based compensation plans totaled $235,000 for the year ended December 31,
1995, $3.3 million (including $1.1 million classified as Compensation to
Terminated Consultant) in 1996, and $3.6 million (including $2.3 million which
is included in the net Settlement to Former Chief Executive Officer) in 1997,
respectively.
F-25
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
The following represents the pro forma effect had the Company valued all of its
stock-based compensation in accordance with SFAS No. 123 using the option -
pricing model assumptions described above.
In thousands
1997 1996 1995
-------- --------- ---------
Net income (loss)
As reported ($116,712) ($6,331) $ 3,331
Pro forma ($120,758) ($7,061) $ 2,171
Basic earnings (loss) per share
As reported ($5.26) ($.48) $ .77
Pro forma ($5.44) ($.53) .50
Diluted earnings (loss) per share
As reported ($5.26) ($.48) $ .70
Pro forma ($5.44) ($.53) .45
The Company's 1993 Stock Option Plan (the "1993 Plan") provides for the issuance
of incentive stock options and non-qualified stock options. Under the terms of
the 1993 Plan, a maximum of 200,000 shares of the Company's common stock may be
issued upon the exercise of stock options granted thereunder. The 1993 Plan
provides for administration by the Company's Board of Directors (or a committee
of the Board of Directors) which, subject to the terms of the 1993 Plan,
determines to whom grants are made and the vesting, timing, amounts and other
terms of such grants. Incentive stock options may be granted only to employees
of the Company, while non-qualified stock options may be granted to the
Company's employees, officers, directors, consultants and advisors. The exercise
price of incentive stock options may not be less than the fair market value of
the Company's stock on the date of grant and the term of these options may not
exceed 10 years; however, with respect to incentive stock options granted to
holders of more than 10% of the Company's common stock, the exercise price may
not be less than 110% of the fair market value of the Company's common stock on
the date of grant and the term of these options may not exceed five years. The
1993 Plan has no options available for new grants as of December 31, 1997.
The Company's 1995 Long-Term Incentive Plan (the "1995 Plan") provides for the
issuance of incentive stock options and non-qualified stock options. The 1995
Plan also provides for awards of restricted stock. Under the terms of the 1995
Plan, as amended, a maximum of 4,000,000 shares of the Company's common stock
may be issued upon the exercise of stock options granted thereunder and a
maximum of 700,000 shares of common stock are available for restricted stock
awards. The 1995 Plan provides for administration by the Company's Board of
Directors (or a committee of the Board of Directors) which, subject to the terms
of the 1995 Plan, determines to whom grants are made and the vesting, timing,
amounts and other terms of such grants. The 1995 Plan provides that the total
number of shares of common stock that may be subject to stock options or
restricted stock awards granted to any person in any calendar year may not
exceed 25% of the maximum number of shares that may be issued and sold under the
Plan. The Company has a policy pursuant to which non-employee directors shall
receive an option to purchase 10,000 shares of Common Stock (i) on the date that
such director first becomes a director, and (ii) each year, on the day
immediately following the Company's annual stockholders' meeting.
F-26
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
A summary of the status of the Company's two stock option plans at December 31,
1997, 1996 and 1995, and changes during the years ended on those dates is
presented below:
<TABLE>
<CAPTION>
1997 1996 1995
--------------- --------------- --------------
WEIGHTED WEIGHTED WEIGHTED
SHARES AVERAGE SHARES AVERAGE SHARES AVERAGE
(000) EXERCISE PRICE (000) EXERCISE PRICE (000) EXERCISE PRICE
------- -------------- ------ -------------- ------ --------------
<S> <C> <C> <C> <C> <C> <C>
Outstanding at
beginning of year 2,570 $ 8.47 1,057 $ 5.23 190 $ 5.33
Granted:
Exercise Price equals
market price 685 6.79 1,206 11.29 552 5.10
Exercise Price is less
than market price -- -- 545 7.23 315 5.38
Exercised (16) (4.44) (195) (5.30) -- --
Forfeited (128) 11.06 (43) (5.28) -- --
------ ------ ------ --------- ------ --------
Outstanding at end of year 3,111 $ 8.02 2,570 $ 8.51 1,057 $ 5.23
====== ====== ====== ========= ====== ========
Options exercisable at end of year 1,950 466 225
Weighted average fair
value of options granted
during the year:
Exercise Price equals
market price $6.79 $ 6.00 $3.28
Exercise Price is less
than market price not applicable $ 9.70 $3.99
</TABLE>
The following table summarizes information about stock options outstanding at
December 31, 1997.
<TABLE>
<CAPTION>
OPTIONS OUTSTANDING OPTIONS EXERCISABLE
------------------- -------------------
SHARES SHARES
RANGE OF OUTSTANDING WEIGHTED- AVERAGE WEIGHTED-AVERAGE EXERCISABLE WEIGHTED-AVERAGE
EXERCISE PRICE AT 12/31/97 REMAINING LIFE EXERCISE PRICE AT 12/31/97 EXERCISE PRICE
- -------------- ----------- ----------------- ---------------- ------------ ----------------
<S> <C> <C> <C> <C> <C> <C>
$3.69 - $ 5.13 662 3.87 $4.95 527 5.02
5.47 - 6.69 665 6.50 6.20 439 6.09
7.00 - 8.63 750 5.25 7.49 445 7.70
9.00 - 12.13 930 3.86 11.35 515 11.60
12.50 - 13.63 104 4.43 13.24 24 13.10
--- ---- ----- --- -----
$3.69 - $13.63 3,111 4.78 $8.02 1,950 $ 7.71
=============== ===== ==== ===== ===== ======
</TABLE>
Not included in the above plans are a total of 625,000 warrants outstanding at
December 31, 1997, issued during 1995 to individuals to purchase common stock at
exercise prices ranging from $5.00 to $5.13. The Company issued 400,000 of the
warrants to a current member of the Company's Board of Directors. During 1995
50,000 warrants were issued to the Company's former Executive Vice President,
General Counsel and Director of the Company prior to his employment with the
Company.
F-27
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
In connection with the Company's 1994 and 1995 public stock offerings, the
Company issued unit purchase options to the underwriters. The 1994 options allow
the holder to acquire 170,000 shares of common stock at $7.25 per share, 170,000
warrants convertible into Common Stock at $6.25 per share and 340,000 warrants
convertible into shares of Common Stock at $8.00 per share. The 1995 options
allow the holder to acquire 161,500 shares of Common Stock at $7.82 per share,
161,500 warrants convertible into shares of Common Stock at $6.25 per share and
323,000 warrants convertible into shares of common stock at $8.00 per share. All
of the options and related warrants, which are convertible into a total of
1,326,000 shares, are outstanding at December 31, 1997.
The Company has 53,200 warrants outstanding at an exercise price of $5.00 per
share which were issued in connection with financing arrangements in prior
years.
In connection with the issuance of the Company's Subordinated Convertible
Debentures, warrants to acquire 319,445 shares of the Company's Common Stock at
$9.00 per share were issued to the underwriter. All of these warrants are
outstanding at December 31, 1997.
The Company granted 100,000 and 324,000 shares of restricted Common Stock to
officers and directors of the Company in 1995 and 1996, respectively. These
restricted stock grants have vesting periods ranging from two to five years. In
1995, the Company recorded a deferred charge in the amount of $350,000. The
aggregate market value at grant date of the restricted stock granted in 1996 was
$4,159,250. Such amounts are being amortized over the vesting periods.
In 1995 and 1996, the Company also granted 50,000 and 55,000 shares respectively
of restricted Common Stock to Coyote Consulting. These restricted stock grants
vested over two and five years, respectively. In 1995, the Company recorded a
deferred charge in the amount of $175,000. In 1996, the market value at grant
date was $708,125. The related consulting agreement with Coyote Consulting was
terminated subsequent to December 31, 1996. The unamortized deferred
compensation was expensed in the fourth quarter of 1996. See Notes 19 and 20.
In 1997 the Company issued to one of its lenders two warrants to purchase an
aggregate of 250,000 shares of Common Stock of the Company at an exercise price
of $7.6875 per share. See Note 6.
F-28
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
[13] EARNINGS PER SHARE
Earnings per common share ("EPS") data were computed as follows:
For the Year Ended December 31:
In thousands, except per share data
<TABLE>
<CAPTION>
1997 1996 1995
--------- --------- ---------
<S> <C> <C> <C>
Income (loss) before extraordinary item $(116,712) $ (6,331) $ 3,025
Extraordinary item -- -- 306
--------- --------- ---------
Net income (loss) $(116,712) $ (6,331) $ 3,331
========= ========= =========
BASIC EPS:
Weighted-average common shares outstanding 22,182 13,222 4,304
========= ========= =========
EPS - income (loss) before extraordinary item $ (5.26) $ (.48) $ .70
EPS - extraordinary item -- -- .07
--------- --------- ---------
EPS - net income (loss) $ (5.26) $ (.48) $ .77
========= ========= =========
DILUTED EPS:
Weighted-average common shares outstanding 22,182 13,222 4,304
Stock options and warrants -- -- 467
--------- --------- ---------
Shares applicable to diluted earnings 22,182 13,222 4,771
========= ========= =========
EPS - income (loss) before extraordinary item $ (5.26) $ (.48) $ .64
EPS - extraordinary item -- -- .06
--------- --------- ---------
EPS - net income (loss) $ (5.26) $ (.48) $ .70
========= ========= =========
</TABLE>
Unexercised stock options and warrants to purchase 5.7 million, 4.9 million and
9.1 million shares of the Company's common stock as of December 31, 1997, 1996
and 1995, respectively, were not included in the computations of diluted EPS
because the exercise prices were greater than the average market price of the
common shares, and the effect of including such shares would be anti-dilutive.
7.8 million and 5.6 million shares of the Company's common stock issuable upon
conversion of convertible debt as of December 31, 1997 and 1996, respectively,
were not included in computations of diluted EPS because the net effect of
including such shares would be anti-dilutive. Unexercised restricted stock
amounting to 228,000 and 379,000 shares of the Company's common stock as of
December 31, 1997 and 1996, respectively, were not included in the computations
of diluted EPS because the effect of including such shares would be
anti-dilutive. As of December 31, 1997 and 1996, respectively, 271,000 and
991,785 shares of the Company's common stock held in escrow, to be released to
the sellers related to certain acquisitions only if certain earnings targets are
achieved, were not included in the computations of diluted EPS because the
effect of including such shares would be anti-dilutive.
F-29
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
[14] COMMITMENTS
The Company and its subsidiaries have non-cancelable operating leases for use of
their facilities and various equipment. These leases may require payment of
various expenses as additional rent. Certain leases contain renewal options and
escalation clauses.
Minimum future rental payments for each of the next five years and thereafter
under non-cancelable operating leases having remaining terms in excess of one
year as of December 31, 1997, are (in thousands):
DATE AMOUNT
- ---- --------
1998 $ 18,659
1999 15,757
2000 11,607
2001 8,644
2002 5,437
Thereafter 14,409
------
Total $ 74,513
========
Rent expense for the years ended December 31, 1997, 1996 and 1995, under various
operating leases amounted to $10.5 million, $5.6 million and $1.6 million,
respectively.
The Company has comprehensive maintenance contracts with its equipment vendors
for the magnetic resonance imaging ("MRI"), computerized tomography ("CT") and
other diagnostic medical equipment. The terms of these contracts are between one
and five years, but may be canceled by the Company under certain circumstances.
The Company has entered into employment agreements with certain officers. The
employment agreements have original terms of two to five years. All of the
agreements provide for a specific amount of annual base salary. Certain of the
agreements provide for incentive bonuses, stated minimum base salary increases,
and options to acquire the Company's Common Stock. In addition, certain of the
employment agreements provide that in the event of certain changes in control of
the Company, the officers may deem their employment terminated and receive lump
sum payments pursuant to terms provided in each of the applicable employment
agreements. The aggregate amount of compensation under all existing employment
agreements, based upon the base salaries in effect at December 31, 1997, for the
remaining terms of the respective employment agreements, was approximately $5.6
million at December 31, 1997.
Each of the Company's Facilities have agreements with radiologists as
independent contractors under long-term agreements to provide all radiology
services to the Facilities. Radiologist compensation ranges between 8%-21% of
net collections attributable to radiology services performed by the radiologist.
[15] LIQUIDITY AND CONCENTRATION OF CREDIT RISKS
During 1997, but for borrowings under the facilities described in Notes 6 and 8,
the Company's cash position deteriorated as a result of higher legal and
accounting fees related to regulatory matters and litigation described in Notes
10 and 20, the repayment of $34.6 million in debt incurred to acquire Facilities
and the payment of $18.9 million in capital expenditures to upgrade and replace
imaging equipment and management information system enhancements. In addition,
cash balances were negatively affected by an increase in bad debt expense and
accounts receivable resulting from a failure to fully collect receivables from
third party payors, in part as a function of the Company's conversion to a new
centralized billing and collection system and in part, as a function of
inefficiencies in realizing on the collection of patient copayments and
deductible payments. This reduction in cash balances has continued during the
first quarter of 1998 and in response, the Company has devoted additional
resources to the collection of accounts receivable and implemented intense
remedial efforts with respect thereto. The Company has also identified a
strategy designed to improve the Company's financial condition, including the
sale of Medical Diagnostics, Inc., as well as the potential sale of other
non-core assets. If the Company's strategy is not sufficient or if collections
cannot be improved to the extent necessary, the Company's liquidity and
financial condition could be materially and adversely affected. In addition, if
the uncertainties with respect to the Company's credit facilities described in
Note 6 cannot be satisfactorily resolved, the Company may be required to pay
down or refinance all or a portion of such credit facilities. In any such event
the Company would likely need to seek new financing, either through an equity
offering, additional borrowing or asset sales. There can be no assurance that
the Company would be able to obtain such new financing or effect such asset
sales in a timely fashion or upon acceptable terms, or if at all.
The Company's imaging centers grant credit without collateral to its patients,
most of whom are residents of the areas where the centers are located and are
insured under third-party payor agreements.
F-30
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
The mix of receivables from third-party payors and patients at December 31,
1997, are as follows:
% OF TOTAL
----------
Medicare & Medicaid 17%
Workers' Compensation 8
Commercial 14
Managed Care 43
Self Pay 4
Other 14
---
Total 100%
===
[16] 401(K) PROFIT SHARING PLAN
Effective in October 1996, the Company amended its 401(k) Pension Plan to a
401(k) Profit Sharing Plan (the "Plan"). The Plan is offered to full-time
employees who have completed six months of service. Eligible employees may make
elective deferrals in any amount up to 15% of their compensation. The Company
contributes 100% of the amount withheld from the Participant's compensation (up
to a maximum of 3%) and may make additional discretionary contributions.
Employer contributions to the Plan totaled $526,000 and $180,000 in fiscal 1997
and 1996, respectively.
[17] EXTRAORDINARY ITEM
During fiscal 1995, the Company settled a note payable principal balance in an
amount less than the recorded liability. In addition, the Company received an
upgrade to the related equipment at no additional cost. The transaction resulted
in a net gain of $306,000 after taxes of approximately $204,000.
[18] INVESTMENTS IN AND ADVANCES TO UNCONSOLIDATED SUBSIDIARIES
In 1997, as the result of losses incurred by Diversified Therapy Corporation
("DTC"), a 1996 unconsolidated investment in a start-up company accounted for
using the equity method of accounting, the Company recorded a loss of $3.6
million in the quarter ended June 30, 1997, representing the Company's entire
recorded investment in DTC. Such loss amount is included in asset impairment
losses as discussed in Notes 2 and 5.
Effective July 1, 1996, the Company entered into a 50/50 joint venture with
Phycor of Jacksonville, Inc., a wholly-owned subsidiary of Phycor, Inc., to
lease outpatient imaging equipment and facilities to affiliated providers in
South Georgia and North Florida through Diagnostic Equity Partners, ("DEP"), a
partnership. The Company initially contributed the fixed assets and related debt
of its Orange Park facility and subsequently the fixed assets of its Salisbury
facility with a combined net book value of $1.1 million. In July 1996, the
Company acquired the remaining 20% of the common stock of Salisbury owned by a
Director and Officer of the Company for $567,000. Two additional centers were
purchased in 1996, and two additional centers were opened in 1997 with an
investment of $1.7 million by the Company. At December 31, 1997 and 1996, the
Company's investment in and advances to DEP was $1.4 million and $3.4 million
respectively. The 1996 amount included $1.2 million of goodwill which was
written off in conjunction with the Asset Impairment Losses discussed more fully
in Notes 2 and 5.
F-31
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
Condensed unaudited financial data of DEP as of December 31, 1997 and 1996, and
for the twelve months ended December 31, 1997 and six months ended December 31,
1996, is as follows:
In thousands
12/31/97 12/31/96
-------- --------
Current Assets $ 444 $ 3,344
Fixed Assets, Net 8,504 7,161
Goodwill 1,412 1,413
Other Assets 695 248
-------- --------
Total Assets $ 11,055 $ 12,166
======== ========
Current Liabilities $ 3,981 $ 3,644
Long-Term Liabilities 5,271 5,691
Partners' Capital 1,803 2,831
-------- --------
Total Liabilities and Capital $ 11,055 $ 12,166
======== ========
Results of Operations
Revenues $ 11,539 $ 2,614
Expenses 12,568 2,827
-------- --------
Net Loss $ (1,029) $ (213)
======== ========
The following is a combined financial summary of five diagnostic centers
acquired in 1996, which the Company is accounting for under the equity method.
The Company's ownership varies between 18% and 42%. The Company's combined
investments in these entities was $3.0 million and $3.2 million as of December
31, 1997 and 1996, respectively, including goodwill of $2.2 million which is
being amortized over 20 years. Results of operations for the year ended December
31, 1996 are from the respective dates that the Company acquired its ownership
interests:
In thousands
12/31/97 12/31/96
------- --------
Current Assets $ 8,180 $ 5,357
Non-Current Assets 5,551 3,098
------- -------
Total Assets $13,731 $ 8,455
======= =======
Current Liabilities $ 3,954 $ 4,213
Non-Current Liabilities 1,667 1,798
Shareholder's Equity 8,110 2,444
------- -------
Total Liabilities and Capital $13,731 $ 8,455
======= =======
Results of Operations
Revenues $12,237 $ 2,678
Expenses 7,224 1,929
------- -------
Net Income $ 5,013 $ 749
======= =======
F-32
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
[19] TERMINATION OF EMPLOYMENT AND CONSULTING AGREEMENTS
On February 3, 1997, Jeffrey Goffman, at the time the Company's Chairman and
Chief Executive Officer, was voluntarily placed on administrative leave by the
Company's Board of Directors. During this administrative leave, he was relieved
of all corporate duties and did not participate in any meetings of the Company's
Board of Directors. On March 25, 1997, Mr. Goffman declared his election to
treat himself as having been terminated without cause by the Company under his
employment contract, thus, invoking constructive termination provisions of his
employment agreement. This action followed the recommendation of a Special
Committee of the Board of Directors reviewing the Company's former relationship
with Coyote Consulting and Keith Greenberg, an employee of Coyote who had
provided services to the Company. For further information, see Note 20 -
Litigation.
On April 24, 1997, the Company and Mr. Goffman entered into a Letter of Intent
(the "Letter") with respect to the resolution of employment related disputes
between them. Pursuant to the terms of the Letter, Mr. Goffman resigned as an
officer, director and employee of the Company effective as of March 31, 1997,
and received $165,000 upon execution of the Letter. On July 11, 1997, the
Company and Mr. Goffman entered into a Settlement Agreement and General Release
(the "Settlement Agreement"), pursuant to which, among other things, the Company
paid Mr. Goffman an additional $33,000 implementing the terms of the letter and
agreed to pay an additional $267,000 in sixteen equal monthly consecutive
installments of $17,000 beginning in August 1997. Mr. Goffman also agreed to
transfer or vote, as required by the Company, all proxies or other agreements by
which he exercised the right to vote or exercise legal control over the
Company's stock in which others have a beneficial interest. As part of this
settlement, it was agreed that all previously vested restricted stock and stock
options granted to Mr. Goffman would be retained by him and all unvested
restricted stock as of March 31, 1997 (220,000 shares) would become vested and
be placed in an escrow account. In addition, unvested options for 100,000 shares
of Company Common Stock which are exercisable at $5.125 per share were placed in
the escrow account. Notwithstanding Mr. Goffman's resignation, these options
will vest in accordance with the schedule originally established at the time
such options were awarded to Mr. Goffman or, if earlier, upon the sale of the
Company or a change of control on or before March 31, 1999. All other options
which were unvested as of March 31, 1997 (specifically the 100,000 options
granted on June 1, 1996 exercisable at $7.125 and the 250,000 options granted on
October 9, 1996 exercisable at $12.125) will vest only upon the sale of the
Company or a change in control on or before March 31, 1999.
The $165,000 paid to Mr. Goffman upon execution of the Letter, the $33,000 paid
within two days of the execution of the Settlement Agreement, the $267,000 to be
paid over sixteen months and unamortized deferred compensation relating to Mr.
Goffman in the amount of $2.3 million were recorded in Settlement with Former
Chief Executive Officer during the second quarter ended June 30, 1997.
On September 30, 1997 the Company entered into a second settlement with Mr.
Goffman which fully resolved the remaining issues between them including
ownership of the escrow account previously established. Pursuant to this
settlement, Mr. Goffman agreed to contribute $1 million to the Company's
settlement of the class actions in the form of $850,000 cash and the forgiveness
of the next nine monthly payments totaling $150,000 which would otherwise be due
to him from the Company under the earlier settlement. Mr. Goffman delivered the
$850,000 to the Company on March 17, 1998. The Company thereafter released its
claim to the securities covered by the Escrow and Settlement Agreement.
F-33
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
During the quarter ended September 30, 1997, a credit of $1.0 million was
recorded in Settlement with Former Chief Executive Officer to reflect the
expected contributions from Mr. Goffman which were subsequently received.
Michael D. Karsch, the Company's former Senior Vice President, General Counsel
and Secretary of the Company, and the Company were parties to a five-year
employment agreement dated June 1, 1996. On February 3, 1997, Mr. Karsch was
placed on administrative leave by the Company's Board of Directors. This action
followed the recommendation of a Special Committee of the Board of Directors
reviewing the Company's former relationship with Coyote Consulting and Keith
Greenberg (See Note 20 - Litigation). During this administrative leave, Mr.
Karsch was relieved of all corporate duties and did not participate in any
meetings of the Company's Board of Directors. On March 25, 1997, Mr. Karsch
declared his election to treat himself as having been terminated without cause
by the Company under his employment contract, thus invoking constructive
termination provisions of his employment agreement. The Company has treated this
election as a resignation. The Company has not yet agreed to any severance
arrangements with Mr. Karsch. The Company is currently exploring, through
counsel, the possibility of resolving any claims with respect to Mr. Karsch's
employment contract. At December 31, 1997, the Company has deferred compensation
totaling $467,000 relating to Mr. Karsch which is included in Deferred Stock
Based Compensation in the accompanying condensed consolidated balance sheet.
Coyote Consulting and Keith Greenberg (an employee of Coyote) have sued the
Company alleging that they are entitled to receive additional cash, stock and/or
options in an unspecified amount in connection with the Company's December 1996
termination of its consulting relationship with Coyote. The Company has not yet
been required to answer the complaint but intends to vigorously defend the
claims and to assert cross-claims exceeding the amount claimed by Coyote and
Greenberg. Management does not expect the outcome to be material to its
financial position or results of operations.
[20] LITIGATION
In January 1997, six separate class action lawsuits were filed against the
Company and certain officers, directors and other parties alleging failure to
make disclosure regarding the background of Keith Greenberg, who had provided
consulting services to the Company through Coyote Consulting and Financial
Services, LLC ("Coyote Consulting"). Four of the lawsuits have been dismissed
and the two remaining suits have been heard in the United States District Court
for the Southern District of Florida, and have been settled in principle
pursuant to a Memorandum of Understanding (the "Memorandum") dated July 31, 1997
and a more detailed Stipulation of Settlement (the "Stipulation") executed by
all persons and filed with the Court on March 6, 1998. The Memorandum and
Stipulation include a denial of any wrongdoing or liability by both the Company
and the individually named defendants. In accordance with the terms of these
documents, the parties agreed to settle all pending class action claims against
the Company (including additional claims based on alleged misstatements of
financial condition) for $5.9 million, payable $588,000 within ten days after
signing; an additional $1.5 million ten days after Court approval of the
proposed notice advising the class of the settlement; and the remaining $3.8
million no later than twenty-five days before a final hearing for approval of
the settlement. The first payment was made by the Company as required on August
11, 1997. The second payment became due and was made on April 4, 1998 and the
final payment is now due in late May 1998. The settlement is subject to a court
approval process expected to take several months. The payments, when made, are
to be deposited into an interest-bearing account to be held in escrow by
plaintiffs' counsel, pending court approval. The Company reached an agreement
with its insurance carrier whereby the insurer has contributed $1.0
F-34
<PAGE>
million toward the Company's settlement obligation in full satisfaction of its
director and officer liability insurance policy obligations. In addition, the
Company's former CEO, Jeffrey Goffman, has contributed $850,000 cash and
$150,000 in debt forgiveness as described in Note 19. The Company is currently
in negotiations in which it is seeking additional contribution from other third
parties. There can be no assurance that the Company will be successful in these
negotiations. During the quarter ended June 30, 1997, the Company recorded a
provision for settlement of lawsuits in the amount of $4.9 million, comprising
the $5.9 million settlement, net of the $1.0 million contribution from the
insurance company. During the quarter ended September 30, 1997, a credit of $1.0
million was recorded in Settlement with Former Chief Executive Officer to
reflect the contribution from Mr. Goffman.
In addition to the class actions described above, two suits have been filed
against the Company by sellers of diagnostic imaging centers who received the
Company's Common Stock in partial payment of the purchase price for their
centers and who allege that undisclosed facts regarding Keith Greenberg's
background were material to their decision to sell. In connection with the first
of these actions (Centre Commons MRI Ltd., et al v. U.S. Diagnostic et al), in
the United States District Court for the Western District of Pennsylvania, the
sellers of multiple centers in Pennsylvania seek to compel the Company to
repurchase approximately 750,000 shares of its common stock at a price of
$12.125 per share and also allege that the Company's failure to register such
shares under the Securities Act of 1933, pursuant to a written contract,
diminished their value. Even if registered, the shares were subject to limited
releases from lock-up until July 1997 when they became tradable pursuant to Rule
144 without the need for registration. In the second such suit (Sanders et al v.
US Diagnostic et al), in the United States District Court for the Eastern
District of New York, four participants in limited partnerships which sold the
Company three imaging centers in New York seek to recover damages of up to $6
per share for approximately 90,000 shares of the Company's Common Stock. The
Company is vigorously defending both suits but there can be no assurances that
the Company will prevail.
In September 1992, Medical Diagnostic, Inc. ("MDI") and its affiliate Greater
Springfield MRI Limited Partnership ("Springfield") (through its general
partner, Western Massachusetts Magnetic Resonance Services, Inc. a subsidiary of
MDI ("WMMRS")), filed suits against Raytel Corporation, Inc. and certain other
parties (collectively, the "Raytel Defendants") seeking a declaration, damages
and equitable relief against the Raytel Defendants. Various counterclaims were
filed against MDI seeking up to $8 million in damages and injunctive relief. The
Company acquired MDI (of which Springfield and WMMRS are direct or indirect
subsidiaries or affiliates) in February 1997. As part of this acquisition the
seller, Advanced NMR Systems, Inc., agreed to indemnify the Company and MDI for
losses incurred in connection with the foregoing litigation. The litigation,
which was heard in the State Superior Court in California, was settled at no
cost to the Company in October 1997.
The Company is currently involved in litigation related to its acquisition of
stock in Integrated Health Concepts, Inc. ("IHC") in August 1996. In March 1997,
litigation was commenced in state court in Harris County, Texas to determine the
respective stock interests of the Company, Don Ballard, Dr. Mohammed Athari and
a key man trust which, together, comprise all of IHC's shareholders. In June
1997, the Court issued a ruling upholding the Company's position that it owns
70% of IHC's stock. Subsequently, IHC appointed a new Board of Directors which
terminated Mr. Ballard's employment as President of IHC. Mr. Ballard filed
additional claims against IHC and the Company alleging that they had breached
fiduciary duties owing to him and that they were obligated to pay him more than
$1.0 million based upon termination of his employment, to provide him with
$250,000 of Company Common
F-35
<PAGE>
Stock, and to repurchase his IHC stock (and that of a key man trust established
for his benefit) for its fair market value which Mr. Ballard contended was
approximately $8 million. The Company and IHC have vigorously contested such
claims and have asserted their own claims against Mr. Ballard aggregating
approximately $1.3 million. The matter was tried during October 1997 and is
currently under consideration by the Court. There can be no assurances that the
Company will prevail. In March 1998, Mr. Ballard filed a request for additional
trial proceedings contending that since the original trial in October 1997, the
Company has denied his rights as a minority shareholder of IHC. The claims
asserted against IHC and the Company by Dr. Mohammed Athari were fully settled
and resolved without additional payments by either IHC or the Company.
In 1997 the Securities and Exchange Commission initiated an investigation into
the Company's relationship with Coyote Consulting and Keith Greenberg, and the
adequacy of the Company's disclosure concerning that relationship. The inquiry
appears to be focused on whether the disclosures with respect to Mr. Greenberg
and Coyote Consulting were in compliance with the federal securities laws. The
Company cooperated fully with the SEC.
The Company could be subject to legal actions arising out of the performance of
its diagnostic imaging services. Damages assessed in connection with, and the
cost of defending, any such actions could be substantial. The Company maintains
liability insurance which it believes is adequate for its present operations.
There can be no assurance that the Company will be able to continue or increase
such coverage or to do so at an acceptable cost, or that the Company will have
other resources sufficient to satisfy any liability or litigation expense that
may result from any uninsured or underinsured claims. The Company also requires
all of its affiliated physicians to maintain malpractice and other liability
coverage.
The Company is also a party to, and has been threatened with, a number of other
legal proceedings in the ordinary course of business. While it is not feasible
to predict or determine the outcome of these matters, and although there can be
no assurances, the Company does not anticipate that the ultimate disposition of
any such proceedings will have a material adverse effect on the Company.
[21] RELATED PARTY TRANSACTIONS
As of January 1, 1995, and amended effective September 1995, the Company entered
into a consulting agreement with Gordon Rausser, a member of the Company's Board
of Directors, to retain his services as an economic consultant to the Company.
The compensation under this agreement is (a) $25,000 cash for each quarter
commencing January 1, 1995, through December 31, 1999, for which he offers or
agrees to serve on the Company's Board of Directors and to provide other
consulting services to the Company; and (b) warrants to acquire 400,000 shares
of the Company's Common Stock immediately exercisable at $5.00 per share through
December 31, 1999.
During 1995, and 1996, respectively, the Company paid legal fees in the amount
of $353,000 and $430,000, respectively, to the law firm of Bachner, Tally,
Polevoy & Misher LLP of which Michael Karsch, a former executive officer and
director of the Company, was a partner until July 1996 (See Note 20). In 1995,
prior to his employment with the Company, Mr. Karsch was granted options to
acquire 50,000 shares of the Company's common stock immediately exercisable at
$5.125 per share for a term of
F-36
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
five years. In connection with his employment agreement, the Company provided to
Mr. Karsch a loan of up to $100,000 for relocation expenses, of which $51,000
was outstanding as of December 31, 1997.
A member of the Company's Board of Directors, Keith Hartley, is the managing
partner of Forum Capital Markets L.P. ("Forum"). Forum was the underwriter of
the Company's $57.5 million Subordinated Convertible Debenture Offering (see
Note 6), and was paid an underwriting fee of $2.9 million. In addition, the
Company sold to Forum, for nominal consideration, warrants which entitle Forum
to purchase 319,445 shares of common stock of the Company at an exercise price
of $9.00 per share. Mr. Hartley was elected to the Board of Directors of the
Company on September 19, 1996, subsequent to the Debenture offering.
In July 1996, the Company consummated the acquisition of all of the outstanding
capital stock of MediTek Health Corporation from HEICO. Laurans A. Mendelson is
the Chief Executive Officer and Chairman of the Board of HEICO. In accordance
with the terms of the acquisition documents, Mr. Mendelson, as designee of
HEICO, was elected by the Shareholders to the Company's Board of Directors on
September 19, 1996. Mr. Mendelson became Chairman of the Board of the Company on
February 2, 1997. On December 1, 1997, Mr. Mendelson resigned from the Board of
Directors.
In connection with the MediTek acquisition, the Company issued a Note to HEICO
for $10 million. On September 10, 1997, certain terms of the Note were amended,
and on September 16, 1997, HEICO sold the Note to Forum, which on the same day
resold the note to 18 individual parties.
In June 1996, the Company loaned the Company's former Chief Executive Officer,
Jeffrey Goffman, $360,000 for 30 days in connection with a private transaction.
Such loan bore interest at a rate of 10% per annum and was repaid in July 1996.
The Company entered into an Installation Agreement ("Installation Agreement")
dated February 27, 1997, and a Network Support Agreement ("Support Agreement")
dated July 31, 1997, with CIERRA Solutions, Inc. ("CSI"). A brother of Todd
Smith, Vice President and Chief Information Officer of the Company, is a
substantial minority shareholder with CSI. CSI has been providing project
management services to the Company in connection with the deployment of a wide
area computer network to over 100 of the Company's locations and other services
since February 1996. The effective date of the Installation Agreement is
February 1, 1997, and has a one-year term. The effective date of the Support
Agreement is July 31, 1997 and has a six-month term. Payments made to CSI in the
year ended December 31, 1997 totaled $1.1 million, including reimbursement for
expenses and equipment purchases of $268,000. Payments made to CSI in the year
ended December 31, 1996 totaled $334,000, including reimbursement for expenses
and equipment purchases of $64,000.
In July 1996, the Company purchased from a member of the Company's Board of
Directors the remaining 20% interest in a subsidiary of the Company. The Company
had purchased an 80% interest in 1995. Of this 80% interest, 13.3% was acquired
from the director and the remaining 66.7% was acquired from non-affiliates. The
purchase price for such transaction was $567,000, which was equal to the
pro-rata price for the original purchase in 1995.
The Company has a policy pursuant to which non-employee directors shall receive
an option under the Company's 1995 Long-Term Incentive Plan to purchase 10,000
shares of Common Stock (i) on the date that such director first becomes a
director, and (ii) each year, on the day of the first Board of Directors meeting
immediately following the Company's annual stockholders' meeting. See Note 12.
F-37
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
On January 20, 1998, Michael O'Hanlon, the Chief Executive Officer of DVI, Inc.,
an affiliate of DVIBC and DVIFS, was elected to the Board of Directors of the
Company. DVIFS and DVIBC are lenders to the Company. See Note 6.
[22] SUBSEQUENT EVENTS
On March 30, 1998, the Company entered into a definitive agreement to sell
certain non-core assets, specifically the Company's mobile subsidiary Medical
Diagnostics, Inc. ("MDI") to Alliance Imaging Inc. for $35.6 million in cash
less debt to be assumed of approximately $6.5 million. The sale, which is
subject to Hart-Scott-Rodino clearance, is expected to close in May 1998. The
proceeds of the sale will be used to reduce the Company's debt and to bolster
the Company's cash reserves, which have been negatively affected by the events
in 1997.
[23] SUMMARIZED QUARTERLY FINANCIAL DATA (UNAUDITED)
<TABLE>
<CAPTION>
1997 (a)
-----------------------------------------------------------------------------
Q1 Q2 Q3 Q4(c) YEAR
----------- ---------- ---------- -------------- ---------
<S> <C> <C> <C> <C> <C>
Total revenues $ 51,401 $ 56,399 $ 55,621 $ 52,801(c) $ 216,222
Net income (loss) 2,034 (11,904) (9,848) (96,994)(c) (116,712)
Net income (loss) per share - basic 0.09 (0.55) (.044) (4.29) (5.26)
Net income (loss per share - diluted 0.09 (0.55) (.044) (4.29) (5.26)
1996 (a)
-----------------------------------------------------------------------------
Q1 (b) Q2 (b) Q3 (b) Q4 YEAR
----------- ----------- ---------- ------ -------
Total revenues $ 12,568 $ 15,615 $ 31,368 42,510 102,061
Net income (loss) 1,032 431 1,108 (8,902) (6,331)
Net income (loss) per share - basic .17 .06 .06 (.41) (.48)
Net income (loss) per share - diluted .14 .03 .05 (.41) (.48)
<FN>
- ----------
(a) Certain amounts have been reclassified to be consistent with the
presentation of the financial statements for the years ended December 31,
1997 and 1996. Additionally, revenues shown during the first three quarters
of 1997 have been reduced for certain radiologist fees which had previously
been treated as operating expenses. Net income (loss) during these periods
was not affected for these reclassifications.
(b) Accounting adjustments reflected in the audited financial statements herein
as of and for the year ended December 31, 1996, were made which resulted in
the restatement of the Company's Forms 10-QSB, filed with the Securities
and Exchange Commission, for the quarters ended March 31, 1996, June 30,
1996, and September 30, 1996. These accounting adjustments primarily relate
to the Company's accounting for acquisitions, dispositions, issuance of
equity securities and stock options and provisions for state and federal
income taxes.
F-38
<PAGE>
US DIAGNOSTIC INC. AND SUBSIDIARIES
- --------------------------------------------------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------
(c) Two entities acquired in 1996 which derive their revenue from management
of diagnostic imaging centers and related medical facilities continued
to conduct their own accounting subsequent to acquisition. Current
management is investigating possible overstatement of accounts
receivable and revenue, and the causes thereof, and any remedies or
other recourse available to it in such case. The effect of revenue
overstatements since acquisition total $2.8 million and were charged
against revenue in the fourth quarter. The purchase accounting for these
entities was also reviewed in conjunction with the evaluation of
intangible and long-lived assets more fully described in Notes 2 and 5.
Impairment losses for these two entities totaled $21.7 million of the
1997 impairment loss total of $92.9 million, substantially all of which
was recorded in the fourth quarter. Management is investigating both
these acquisitions to determine an appropriate course of action. Current
management considered but decided against restating prior quarters for
the effect of these significant fourth quarter adjustments as there was
not previously sufficient evidence available to quantify and prove
permanent impairment.
</FN>
</TABLE>
F-39
<PAGE>
US DIAGNOSTIC INC.
SCHEDULE II
VALUATION AND QUALIFYING ACCOUNTS
YEARS ENDED DECEMBER 31, 1997, 1996 AND 1995
IN THOUSANDS
<TABLE>
<CAPTION>
Column A Column B Column C Column D Column E
Additions
Balance at Charged to Charged to Balance at
Beginning of Costs and Other Deductions End of
Description Period Expenses Accounts (describe) Period
YEAR ENDED DECEMBER 31, 1997
<S> <C> <C> <C> <C> <C>
Reserves deducted from assets to which they apply:
Allowance for possible loss on
accounts receivable $ 9,670 $15,179 $ 1,822(b) $ 9,359(a) $17,312
Allowance for possible loss on
other receivables $ 923 $ 2,451 $ 3,491(b) $ 6,865(a) $ --
YEAR ENDED DECEMBER 31, 1996
Reserves deducted from assets to which they apply:
Allowance for possible loss on
accounts receivable $ 5,872 $ 4,016 $ 5,008(b) $ 5,226(a) $ 9,670
Allowance for possible loss on
other receivables $ -- $ -- $ 923(b) $ -- $ 923
YEAR ENDED DECEMBER 31, 1995
Reserves deducted from assets to which they apply:
Allowance for possible loss on
accounts receivable $ 1,151 $ 577 $ 4,144(b) $ -- $ 5,872
Allowance for possible loss on
other receivables $ -- $ -- $ -- $ -- $ --
<FN>
- ----------
(a) Accounts written off.
(b) Amount represents the allowance for estimated uncollectible portion of
acquired accounts receivable from the various acquisitions.
</FN>
</TABLE>
<PAGE>
EXHIBIT INDEX
EXHIBIT DESCRIPTION
4.7 First Supplemental Indenture to Indenture relating to 9% Subordinated
Convertible Debenture dated as of March 24, 1998.
21 Subsidiaries of the Registrant
23.1 Consent of Arthur Andersen LLP
23.2 Consent of Moore Stevens, P.C.
27 Financial Data Schedule
- -------------------------------------------------------------------------------
US DIAGNOSTIC INC.,
(formerly U.S. DIAGNOSTIC LABS INC.)
Company
and
AMERICAN STOCK TRANSFER & TRUST COMPANY,
Trustee
FIRST SUPPLEMENTAL INDENTURE
Dated as of March 24, 1998
TO
INDENTURE
Dated as of March 29, 1996
===========================
$57,500,000
9% Subordinated Convertible Debentures Due 2003
- -------------------------------------------------------------------------------
<PAGE>
FIRST SUPPLEMENTAL INDENTURE
First Supplemental Indenture dated as of March 24, 1998 (the "First
Supplemental Indenture") made and entered into by and between US Diagnostic Inc.
(formerly U.S. Diagnostic Labs Inc.) (the "Company") and American Stock Transfer
& Trust Company, as Trustee (the "Trustee"), under the Indenture dated as of
March 29, 1996 between the Company and the Trustee (the "Indenture"). Terms used
but not defined herein shall have the meanings given them in the Indenture.
WHEREAS, Section 9.2 of the Indenture provides that the Company and the
Trustee may, with the written consent of the Holders of at least a majority in
aggregate principal amount of the then outstanding Debentures, enter into
indentures supplemental thereto; and
WHEREAS, all things necessary to make this First Supplemental Indenture
a valid, binding and legal instrument supplemental to the Indenture have been
performed, subject to the terms of the Indenture, including but not limited to
obtaining the requisite consent of the Holders; and
NOW, THEREFORE, each party agrees as follows for the benefit of the
other party and for the equal and ratable benefit of the Holders of the
Debentures:
ARTICLE I
Amendments
Section 1. Section 1.1 of the Indenture is hereby amended to add the following
definition:
"Extraordinary Items" means, for purposes of calculating
Operating Cash Flow, expenses or losses incurred by the Company for the
settlement of certain shareholder litigation, the conduct of certain
proceedings with respect to the NASDAQ National Market and certain
investigatory proceedings before the Securities and Exchange
Commission, and related accounting, legal and professional expenses in
the aggregate amount of $10,000,000."
Section 2. The definition of "Operating Cash Flow" set forth in Section 1.1 of
the Indenture is hereby amended to add prior to the period a new clause (v) as
follows:
", plus (v) Extraordinary Items but only to the extent such
Extraordinary Items or a portion thereof were actually
included in computing such Consolidated Net Income for such
period."
2
<PAGE>
ARTICLE 2
Miscellaneous
Section 3. This First Supplemental Indenture shall be effective with respect to
all Debt incurred on or after January 1, 1998.
Section 4. The recitals contained herein shall be taken as the statements of the
Company and the Trustee assumes no responsibility for their correctness. The
Trustee makes no representation as to the validity or sufficiency of this First
Supplemental Indenture.
Section 5. This First Supplemental Indenture shall be governed by and construed
in accordance with the laws of the jurisdiction which governs the Indenture and
its construction.
Section 6. This First Supplemental Indenture may be executed in any number of
counterparts and by the parties hereto in separate counterparts, each of which
when so executed shall be deemed to be an original and all of which taken
together shall constitute one and the same agreement.
IN WITNESS WHEREOF, the parties have caused this First Supplemental
Indenture to be executed as of the day and year first above written.
US DIAGNOSTIC INC.
By:____________________________
Joseph A. Paul
Chief Executive Officer,
President and Director
Attest:
- --------------------------------
Francis J. Harkins, Jr., Esq.
Secretary
AMERICAN STOCK TRANSFER & TRUST COMPANY
By:____________________________
Name: Herbert J. Lemmer
Title: Vice President
Attest:
- -------------------------
Susan Silber
Assistant Secretary
3
EXHIBIT 21
<TABLE>
<CAPTION>
SUBSIDIARIES OF THE REGISTRANT
STATE OF CORPORATE
NAME INCORPORATION % OWNED
- ---- ------------------ -------
<S> <C> <C>
Advanced Medical Imaging Center, Inc. Delaware 100.00%
Affiliated Medical Imaging Network, Inc. California 100.00%
AH Imaging Center, Inc. Delaware 100.00%
Columbus Diagnostic Center Inc. Delaware 100.00%
Commumity Radiology of Virginia Inc. Virginia 100.00%
Computerized Medical Imaging Center Inc. Delaware 56.90%
DI Imaging Center Inc. Delaware 100.00%
Eastside Imaging, Inc. Texas 100.00%
Fannin Street Imaging, Inc. Texas 100.00%
FCA of Van Nuys, Inc. Delaware 100.00%
Finance Funding Corp. Florida 100.00%
First Choice Networks, Inc. Florida 100.00%
Fort Bend Imaging, Inc. Texas 100.00%
Futurecare Affiliates, Inc. Delaware 100.00%
Gulf Coast Imaging Services, Inc. Texas 100.00%
Heights Imaging Center Inc. Delaware 100.00%
Imaging Management Services Inc. Delaware 100.00%
Integrated Health Concepts Inc. Texas 70.00%
Kaley Imaging, Inc. Florida 100.00%
Laborde Diagnostic Inc. Louisiana 80.00%
LB Imaging Center, Inc. Delaware 100.00%
Medical Marketing Development, Inc. New York 100.00%
Medical Imaging Centers of America, Inc. California 100.00%
Medical Imaging Equipment Leasing, Inc. Florida 100.00%
MediTek-Broward, Inc. Florida 100.00%
MediTek-Chatham Industries, Inc. Florida 100.00%
MediTek-Greystone, Inc. Florida 100.00%
MediTek-HE, Inc. Florida 100.00%
MediTek-ICOT, Inc. Florida 100.00%
MediTek-Newark, Inc. Florida 100.00%
MediTek-Palm Beach Gardens, Inc. Florida 100.00%
MediTek-Palms, Inc. Florida 100.00%
MediTek-PBGMRI, Inc. Florida 100.00%
MediTek-Premier North, Inc. Florida 100.00%
MediTek-Premier, Inc. Florida 100.00%
MediTek-Sun Coast, Inc. Florida 100.00%
MediTek Anesthesia, Inc. Florida 100.00%
MediTek Capital Corp. Florida 100.00%
MediTek Gwinnet, Inc. Florida 100.00%
MediTek Health Care Management, Inc. Florida 100.00%
MediTek Health Corporation Florida 100.00%
MediTek Industries, Inc. Florida 100.00%
MediTek Therapy, Inc. Florida 100.00%
MICA CAL II, Inc. California 100.00%
MICA CAL X, Inc. California 100.00%
MICA FLO I, Inc. California 100.00%
MICA Imaging, Inc. Illinois 100.00%
MICA OR I, Inc. California 100.00%
<PAGE>
MICA Pacific, Inc. California 100.00%
Modesto Imaging Center Inc. Delaware 100.00%
Owner Diagnostics, Inc. California 67.53%
San Antonio Diagnostic Imaging, Inc. (f/k/a Hamiltion
Wolfe Imaging, Inc.) Texas 100.00%
San Francisco Magnetic Resonance Center, Inc. Delaware 100.00%
Santa Fe Imaging Center Inc. Delaware 100.00%
South Coast Radiologists, A Corporation Oregon 100.00%
Steeplechase Diagnostic Center, Inc. Texas 100.00%
Townley Group, Inc. California 50.10%
US Cancer Care, Inc. California 51.00%
US Imaging, Inc. Texas 100.00%
USD Dayton Inc. Delaware 100.00%
Medical Diagnostics, Inc. Delaware 100.00%
Western Massachusetts Magnetic Resonance Services, Inc. Massachusetts 100.00%
MRI Associates, Inc. Massachusetts 100.00%
MDI Investments, Inc. Massachusetts 100.00%
Greater Boston MRI Services, Inc. Massachusetts 100.00%
Mobile MRI of Western Mass., Inc. Massachusetts 100.00%
Central Massachusetts MRI Services, Inc. Massachusetts 100.00%
Casco Bay MR Services, Inc. Maine 100.00%
MDI Finance & Leasing, Inc. Massachusetts 100.00%
Merrimack Scanning, Inc. New Hampshire 100.00%
MDI-New York, Inc. New York 100.00%
Meritus PLS, Inc. Virginia 100.00%
Greater Springfield MRI, Inc. Massachusetts 100.00%
MICA CAL III, Inc. California 100.00%
MICA CAL IV, Inc. California 100.00%
MICA CAL I, Inc. California 100.00%
MediTek-Wellington Corp. Florida 100.00%
MICA CAL VII, Inc. California 100.00%
MediTek-Winter Park, Inc. Florida 100.00%
Orange Park Diagnostic Center, Inc. Delaware 100.00%
LINC Medical Imaging, Inc. Delaware 100.00%
FCA Management, Inc. Delaware 100.00%
USDL Pittsburgh, Inc. Delaware 100.00%
US Heartcare Management, Inc. (f/k/a Lee Imaging Group) New York 100.00%
Chatham MRI, Inc. New Jersey 100.00%
Salisbury Imaging Inc. Florida 100.00%
</TABLE>
EXHIBIT 23.1
CONSENT OF ARTHUR ANDERSEN LLP
As independent certified public accountants, we hereby consent to the use of our
report dated April 13, 1998, included in this Form 10-K, into the Companys
previously filed Registration Statements File Nos. 333-45879, 333-05395,
333-13033, 333-13035, and 333-16901.
ARTHUR ANDERSEN LLP
West Palm Beach, Florida,
April 13, 1998.
EXHIBIT 23.2
CONSENT OF MOORE STEVENS, P.C.
As independent certified public accountants, we hereby consent to the use
of our report dated February 20, 1996, included in this Form 10-K, into the
Company's previously filed Registration Statements, File Nos. 333-45879,
333-16901, 333-05395, 333-13033, and 333-13035.
On July 1, 1996, the firm of Mortenson and Associates, P.C. changed its
name to Moore Stephens, P.C.
MOORE STEPHENS, P.C.
Certified Public Accounts
Cranford, New Jersey
April 13, 1998
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE BALANCE
SHEET AND STATEMENT OF OPERATIONS AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE
TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 12-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-START> JAN-01-1997
<PERIOD-END> DEC-31-1997
<CASH> 17,460
<SECURITIES> 0
<RECEIVABLES> 76,049
<ALLOWANCES> (17,312)
<INVENTORY> 0
<CURRENT-ASSETS> 83,928
<PP&E> 116,897
<DEPRECIATION> (25,330)
<TOTAL-ASSETS> 287,999
<CURRENT-LIABILITIES> 69,286
<BONDS> 214,563
0
0
<COMMON> 229
<OTHER-SE> 25,111
<TOTAL-LIABILITY-AND-EQUITY> 287,999
<SALES> 0
<TOTAL-REVENUES> 216,222
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 297,233
<LOSS-PROVISION> 17,630
<INTEREST-EXPENSE> 19,114
<INCOME-PRETAX> (116,123)
<INCOME-TAX> (1,839)
<INCOME-CONTINUING> (116,712)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (116,712)
<EPS-PRIMARY> (5.26)
<EPS-DILUTED> (5.26)
</TABLE>
